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ABSTRACT 
Metabolites are small molecules present in a biological system that have 
multiple important biological functions. Changes in metabolite levels reflect 
genetic and environmental alterations and play a role in multiple diseases. 
Metabolomics is a discipline that aims to analyze all the small molecules in a 
biological system simultaneously. Since metabolites represent a diverse group 
of compounds with varying chemical and physical properties with a wide 
concentration range, metabolomic analysis is technically challenging. Due to 
its high sensitivity and selectivity, mass spectrometry coupled with 
chromatographic separation is the most commonly used analytical tool. 
Currently, there is no comprehensive universal analytical tool to detect all 
metabolites simultaneously and multiple methods are required. The aim of 
this study was to develop and apply mass spectrometry-based analytical 
methods for metabolomics studies.  
Neonatal rodents can fully regenerate their hearts after an injury. 
However, this regenerative capacity is lost within 7 days after birth. The 
molecular mechanism behind this phenomenon is unknown and 
understanding the biology behind this loss of regeneration capacity is 
necessary for the development of regeneration-inducing therapies. To 
investigate this mechanism, changes in mouse heart metabolite, protein, and 
transcript levels during the early postnatal period were studied. Non-targeted 
metabolomics methods utilizing liquid chromatography-mass spectrometry 
(LC-MS) and two-dimensional gas chromatography-mass spectrometry 
(GCxGC-MS) were applied to detect the metabolic changes of neonatal mouse 
hearts. Two complementary techniques increased metabolite coverage. A total 
of 151 identified metabolites showed differences in the neonatal period, 
reflecting changes in multiple metabolic pathways. The most significant 
changes observed in all levels (metabolite, protein, and transcript) were 
branched chain amino acid (BCAA) catabolism, fatty acid metabolism, and the 
mevalonate and ketogenesis pathways, thus revealing possible associations 
with regeneration capacity or regulation of the cardiomyocyte cell cycle.  
Insulin resistance (IR), metabolic syndrome, and type 2 diabetes have 
been shown to induce metabolic changes; the origin of the changes is 
unknown. In this study, human serum metabolite profiles from non-diabetic 
individuals were associated with IR. Gut microbiota were identified as a 
possible origin of the metabolic changes. Serum metabolites were detected 
with GCxGC-MS and lipids with LC-MS method. In total, 19 serum metabolite 
clusters were significantly associated with the IR phenotype, including 26 
polar metabolites from five separate clusters and 367 lipids from 14 clusters. 
IR and changed metabolites were further associated with gut microbiota 
metagenomics and gut microbiota functional modules, showing that gut 
microbiota impacts the human serum metabolites associated with IR. 
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Individuals with the IR phenotype had increased BCAA levels, which was 
influenced by bacterial species with increased BCAA biosynthesis potential 
and the absence of species with active bacterial inward BCAA transport.  
Sample throughput is often limited when chromatographic separation 
is used in metabolomics applications; a short analysis time is of great 
importance in large metabolic studies. The feasibility of direct infusion 
electrospray microchip MS (chip-MS) for global non-targeted metabolomics 
to detect metabolic differences between two cell types was studied and was 
compared to the more traditional LC-MS method. We observed that chip-MS 
was a rapid and simple method that allowed high sample throughput from 
small sample volumes. The chip-MS method was capable of separating cells 
based on their metabolic profiles and could detect changes of several 
metabolites. However, the selectivity of chip-MS was limited compared to LC-
MS and chip-MS suffers more from ion suppression. 
Many biologically important low-abundance metabolites are not 
detectable with non-targeted metabolomics methods and separate more 
sensitive targeted methods are required. An in-house developed capillary 
photoionization (CPI) source was shown to have high ion transmission efficacy 
and high sensitivity towards non-polar compounds such as steroids. In this 
study, the CPI prototype was developed to increase its sensitivity. The 
feasibility of the ion source for the quantitative analysis of biological samples 
was studied by analyzing 18 endogenous steroids in urine with gas 
chromatography capillary photoionization tandem mass spectrometry (GC-
CPI-MS/MS). The GC-CPI-MS/MS method showed good chromatographic 
resolution, acceptable linearity and repeatability, and low limits of detection 
(2-100 pg mL-1). In total, 15 steroids were quantified either as a free steroid or 
glucuronide conjugate from the human urine samples.  
Additionally, the applicability of the CPI interface for LC applications 
was explored for the first time using low flow rates. The feasibility of the LC-
CPI-MS/MS for the quantitative analysis of four steroids was studied in terms 
of linearity, repeatability, and limits of detection. The method showed good 
quantitative performance and high sensitivity at a low femtomole level.  
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1 REVIEW OF THE LITERATURE 
1.1 METABOLITES AND METABOLOME 
Metabolites are small molecules (MW <1500 Da) present in a biological 
system that play important roles in several biological functions, such as energy 
production and storage, cell signaling and regulation, or as building blocks for 
multiple biological components.1–3 Metabolites can be divided into different 
subclasses based on their origin. Endogenous metabolites are formed during 
intracellular metabolism in a biological system, whereas exogenous 
metabolites (i.e. drugs, food nutrients, environmental pollutants) are 
introduced from outside the system. Metabolites can also originate from 
interactions between symbiotic biological systems, such as host (e.g. human) 
and gut microbiota.4,5 These metabolites represent a diverse group of 
molecules with varying concentrations from several chemical classes (Figure 
1). Metabolites differ in molecular weight and chemical and physical 
properties, such as hydrophobicity/hydrophilicity, acidity/basicity, volatility, 
and solubility. The metabolome represents the collection of all small molecule 
metabolites in a biological system and can be analyzed with metabolomics.1–3 
 
 
 
Figure 1 Examples of different metabolite structures; A) Hypoxanthine, B) Leucine, C) S-Adenosyl 
methionine, D) Lactic acid, E) Phosphatidylcholine(18:0/20:4),  F) β-Estradiol, G) Glucose 1,6-
bisphosphate 
1.2 OMICS CASCADE  
The main biological components can be simplified into four categories; genes, 
transcripts, proteins, and metabolites (Figure 2). The -omics suffix refers to 
holistic technologies that seek to comprehensively measure all of these 
biological components, specifically genomics, transcriptomics, proteomics, 
and metabolomics (Figure 2). Systems biology (multiomics) studies all these 
biological components and their complex interactions inside the system.6,7   
REVIEW OF THE LITERATURE 
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Figure 2 Overview of different -omics platforms and applied analytical techniques. LC-MS; liquid 
chromatography-mass spectrometry, GC-MS; gas chromatography-mass spectrometry, MS; mass 
spectrometry, NMR; nuclear magnetic resonance spectroscopy.   
1.2.1 METABOLOMICS 
 
Metabolomics is a growing discipline that aims to detect and 
comprehensively analyze all the small molecules in a biological system 
simultaneously and compare the levels between different conditions (i.e. 
disease, diet, treatment, or lifestyle).1–3 Changes in metabolite levels reflect cell 
function, as they represent the downstream amplification of changes occurring 
at the mRNA or protein levels. Whereas genes and genetic risk indicate what 
might happen, metabolites indicate what is currently occuring and are closest 
to phenotype, simultaneously representing genetic and environmental 
alterations (Figure 2).2,8 It is also known that due to protein modifications, 
signaling and enzymatic activity does not depend only on the protein levels.9 
Thus metabolomics provides complementary information compared to other 
omics and a systems-wide understanding of biological function.8 The 
metabolome is also highly dynamic in nature and metabolite turnover can be 
much faster and changes in the metabolite levels can be greater compared to 
the proteome and transcriptome.10,11 Metabolomics also offers higher 
analytical throughput compared to proteomics and transcriptomics, which 
significantly lowers the costs of analysis. However, the chemical variety of 
metabolites is large compared to genes or transcripts, which consist only of 
four nucleotides, or proteins, which are built from 20 amino acid subunits and 
are commonly detected with a single analytical platform.10 Due to the high 
diversity of the chemical and physical properties of metabolites, there is 
currently no comprehensive universal analytical tool to detect all metabolites 
simultaneously. Accordingly, multiple strategies are employed for a wide 
metabolite coverage.11 An additional challenge is the highly variable 
metabolite concentrations, which makes analysis technically challenging. The 
most commonly utilized analytical tools in metabolomics are mass 
 19 
spectrometry (MS) or nuclear magnetic resonance spectroscopy (NMR).11 
Metabolomics can be further divided into smaller branches with a focus on 
certain chemical classes, such as lipids (lipidomics),12,13 steroids 
(steroidomics),14 and sugars (glycomics).15 
1.2.1.1 Non-targeted metabolomics 
 
Non-targeted metabolomics or metabolic profiling aims to detect and 
compare the levels of all metabolites in a biological system without prior 
knowledge of the compounds of interest. This is a useful approach in studies 
with a general hypothesis of expected metabolic differences, but where no 
specific scientific hypothesis on the differences exists. Thus, non-targeted 
metabolomics is hypothesis creating and can provide novel insights into 
metabolic changes related to the biological question.16 
Non-targeted metabolomics aims to detect metabolites with as wide and 
universal coverage as possible from several metabolite classes. As typically no 
standard compounds are applied, the analysis is semi-quantitative with 
relative abundance; absolute concentrations cannot be determined. The 
repeatability and reliability of non-targeted methods are not as good as that of 
targeted methods and validation is more difficult. For reliable results, careful 
experimental design and quality control is necessary and in an ideal case the 
findings are later validated with a targeted approach.17,18  
1.2.1.2 Targeted metabolomics  
 
Targeted metabolomics is focused on a previously determined set of 
metabolites of interest that are analyzed to test a specific hypothesis.19 
Targeted metabolomics methods are usually also quantitative based on 
appropriate standard compounds and labeled internal standards. In fact, such 
methods are classical quantitative methods that have been applied in 
bioanalysis for a long time. Targeted methods are commonly specific, 
sensitive, accurate, and are usually applied in the validation and confirmation 
of the hypothesis. Targeted methods are also widely applied for the analysis of 
metabolites of which the concentrations are too low to be detected with non-
targeted methods. To achieve high specificity, sample preparation and analysis 
methods can be optimized for certain compound classes, such as bile acids,20 
acylcarnitines,21 acyl-coenzyme A:s,22 amino acids,23 and steroids.24 The 
methods can also lie between targeted and non-targeted, referred to as semi-
targeted methods.24,25  
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1.2.1.3 Lipidomics 
 
Lipidomics is a branch of metabolomics that aims to analyze all lipid species 
simultaneously and compare the lipid content between different 
conditions.12,13 Lipidomics has become an important research field due to the 
increased awareness of lipid functions in the cell and their role in many 
common diseases.12,13 The polarity of lipids vary substantially from other 
common metabolite classes, which can be commonly analyzed under 
classification of “polar metabolites”. Thus, the selection of extraction and 
analysis method in lipidomics is commonly based on the non-polar properties 
of lipids.12,13 The challenges in lipidomics, such as structural diversity and the 
wide concentration range of lipids, are similar to metabolomics in general. 
However, lipids usually consist of repeating building blocks (fatty acid chains 
and phospholipid functional groups), which assist in analysis and 
identification.12,13 
1.2.1.4 Applications of metabolomics and lipidomics 
 
Metabolomics has become an important and widely applied tool in plant,26 
environmental,27  food and nutrition,28 microbial,29 and mammalian 
studies.2,3 Mammalian and human metabolomics have primarily been applied 
for biomarker discovery in disease diagnostics and prognosis, understanding 
disease mechanisms, identifying novel drug targets, drug therapeutics, and 
precision medicine.2,3 Metabolomics has been used to study several diseases 
or risk factors of disease progress, such as Parkinson’s disease,30 Alzheimer’s 
disease,31 diabetes,32 neuropsychiatric diseases (i.e. schizophrenia, 
depression, anxiety, psychosis),33,34 several cancers,35 multiple sclerosis,36 
cardiovascular diseases,37 psoriasis,38 traumatic brain injury,39 and stroke40. 
The list is endless and multiple diseases, including genetic disorders, have 
been studied with metabolomics.41 Screening of metabolic inborn errors is 
already routinely performed in clinics.42,43  Yet, the emphasis of metabolomic 
studies is more in multi-factorial disorders that do not have a single genetic 
cause but are triggered by multiple factors, interactions, and lifestyle. Such 
studies aim to identify possible sensitive and specific biomarkers for clinical 
diagnostics or early prognosis in cases where there are no current markers or 
the current markers are poor or require expensive analyses.44,45 Another 
important application of metabolomics includes studying disease mechanisms 
or searching for possible drug targets and often in combination with 
other -omics studies.2 Cellular metabolic changes and mechanisms related to 
drug treatment efficacy (pharmacometabolomics) and drug side-effect 
variation is also interesting and studied field.46,47 Pharmacometabolomics 
aims to facilitate personalized medicine and the selection of treatments for 
different subpopulations of patients to maximize drug efficacy and to 
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minimize toxicity and side effects.46 In particular, metabolomics for different 
cancer therapies and for statins have been investigated. 47,48 
The interaction of human and gut microflora metabolites can have an 
impact on human health and can offer insights on lifestyle and diet. 
Accordingly, interest in metabolites produced by intestinal microbes has 
increased.4,5,49 The relationships between gut microbiota metabolomic 
interactions and diabetes,5 neurodegenerative disorders,4 and non-alcoholic 
fatty liver disease have been examined.50  
Different mechanistic and metabolic regulation studies have also adopted 
the application of stable heavy isotope labeling (13C, 15N, 2H, 18O) to study the 
reaction rates and metabolic fluxes inside the system.51,52 When cells are grown 
on a heavy isotope-enriched substrate, the heavy isotopes propagate through 
the metabolic network according to the active metabolic pathways.51,52 This is 
referred to as fluxomics, which is a separate branch of metabolomics that uses 
labeled patterns to identify active metabolic pathways in cells to characterize 
the metabolic phenotype.51,52 
Cells even in isogenic culture are heterogeneous populations that 
encapsulate different cell phenotypes due to genetic, epigenetic, and 
environmental factors.53 Single-cell metabolomics aims to study and 
understand phenotypic heterogenity.54,55 This can be useful in the study of 
therapeutic effects for different cell phenotypes or to identify metastatic cancer 
cells.54,55 While genes and transcripts can be multiplied with polymerase chain 
reaction (PCR), amplification of metabolites is impossible, which is a unique 
challenge in single-cell metabolomics studies.54,55 In the analysis of tissues, cell 
heterogeneity is also present. When a tissue sample is homogenized, 
information on the original distribution of compounds in the tissue is lost. To 
study the spatial distribution of metabolites and drugs in the sample, mass 
spectrometry imaging (MSI) is commonly applied.56  
1.3 ANALYTICAL METHODS IN METABOLOMICS AND 
LIPIDOMICS 
Analytical platforms in metabolomics should be highly sensitive, accurate, 
reproducible, and able to characterize simultaneously as large portion of the 
metabolome as possible. These demands can only be partially fulfilled either 
with MS or NMR.11,17,57 Although NMR is universal, non-destructive, and 
suitable for a wide range of chemical structures, it suffers from low sensitivity 
and detection is limited to mainly high-abundance metabolites.11,57 On the 
other hand, MS has high sensitivity and specificity.11,17 MS-based 
metabolomics can be performed by infusing sample directly, although MS is 
commonly coupled with a separation technique such as liquid 
chromatography (LC),2,58,59 gas chromatography (GC),59,60 or capillary 
electrophoresis (CE).59,61 All these methods have their own limitations and 
advantages and none of these methods can detect all metabolites 
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simultaneously due to varying physicochemical properties and the wide 
concentration ranges of the metabolites. A typical workflow in metabolomics 
contains sampling, sample pretreatment, analysis, data processing, data 
analysis, and data interpretation (Figure 3). 
Figure 3 Workflow of non-targeted metabolomics analysis.  
1.3.1 STUDY AND EXPERIMENTAL DESIGN 
 
Metabolomics study design is one of the most important parts of a 
successful experiment.11,18 Experimental studies compare different treatments 
or multiple experimental factors at once in controlled manner. However, in 
metabolomics, the experiments are more often observatorial studies, such as 
case-control, cross-sectional, cohort, or longitudinal studies.11,18 A case-
control study is where the subjects with a certain condition (i.e diet, disease) 
(cases) are compared to otherwise similar subjects without the condition 
(controls). A cross-sectional study compares a population at a certain time 
point, a cohort compares a group of people with common characteristics (i.e 
birth, exposure), and a longnitudinal study is a cohort study followed over a 
long period of time.11,18 In metabolomics, it is important to discriminate the 
possible covariables (e.g. age, sex, medication, and clinical variables), which 
may affect the observed metabolic differences. Thus, cases and controls should 
be carefully matched considering all possible covariables.11,18 
A sufficient number of samples is needed for statistical and prediction 
power in metabolomics. However, compromises are commonly made 
according to costs, time, and available resources. In biomarker discovery, the 
study is usually designed to create a training set for biomarker modeling and 
the test set is used to independently validate the diagnostic performance of the 
tentative biomarkers.18,58  
Sampling and sample storage are important parameters that affect the 
detected metabolite levels. Sampling protocols should be similar even if 
samples are collected at multiple sites over a long period of time.62 The impact 
of blood sample collection conditions (i.e. fasting time, season, and time of day 
for blood collection, sample collection tubes) on metabolite levels is evident.62 
In experimental design, recommended steps and points to consider include 
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randomization prior to sample preparation and injection order, avoiding 
possible errors due to sampling and sample storage, sample preparation, 
analytical response and correction over time, and application of quality-
control (QC) samples.18 
1.3.2 SAMPLE MATRIXES, COLLECTION, AND STORAGE 
 
The sample matrix in metabolomics can be any biological matrix, although 
typically biofluids such as serum,21,63 plasma,23,38,63 or urine24,64,65 are practical 
especially for biomarker search purposes, as such samples are homogenous 
and easy to acquire. Other matrixes, such as cerebrospinal fluid,66 saliva,67 
feces,68 tissues,59,69 or sweat70 have also been used. The selected sample type 
depends on the application, the studied phenomena, and the availability of the 
sample. Biofluids are easy to collect and provide a snapshot of a mammalian 
system. For example, cerebrospinal fluid closely reflects concentrations in the 
brain and has been used in studies of neural disorders.30,31 On the other hand, 
tissues are more specific and are frequently used to study the biological 
mechanisms of organs.59 However, for clinical diagnostics tissues are not 
convenient and sampling should preferably be fast and easy.45 
A proper and objective sample collection, storage, and sample 
pretreatment are key issues in the success and reliability of metabolic 
measurements. Biological samples should ideally be stored at low 
temperatures (e.g. -80°C) immediately after collection and the number of 
freeze-thaw cycles should be minimal. Sampling should be representative and 
sample containers should not cause non-specific binding or surface 
adsorptions.71 An anticoagulant in plasma sample preparation (e.g. heparin, 
EDTA, or citrate), sample collection tube selection, and sample collection 
protocol may influence the detected metabolites and all samples should be 
treated equally to avoid any bias.62,72,73 
Quenching is a process that aims to eliminate metabolic fluxes and 
interconversion to other metabolites by inactivating enzymes in the sample.  
Quenching is particularly important with cell and tissue samples.58,71  
Quenching can be part of sampling (e.g. cell harvesting and tissue sectioning) 
or integrated within the sample pretreatment.74 This is typically performed by 
adding organic solvent or buffer solution, increasing or decreasing the 
temperature, or both.58,71,75,76 The most common quenching methods are 
addition of ice-cold acetonitrile (ACN), methanol (MeOH), buffer solutions 
(e.g. ammonium bicarbonate, phosphate buffered saline [PBS] or sodium 
chloride), or snap-freezing in liquid nitrogen.58,71,75,76  
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1.3.3 SAMPLE PRETREATMENT 
 
Sample pretreatment of biological samples in non-targeted metabolomics 
should preferably be universal and minimal to prevent potential loss or 
conversion of metabolites.17,75,77 Sample pretreatment requirements depend 
on the matrix, analytes, and analytical method. In metabolomics, sample 
pretreatment can commonly consist of homogenization, cell lysis, protein 
precipitation (PPT), liquid-liquid extraction (LLE), solid-phase extraction 
(SPE), derivatization, evaporation, and reconstitution.17,69,74,75,77 Sample 
pretreatment can be quite straightforward, for example removing proteins, 
salts, urea, or other interfering compounds. Therefore, for biofluids with low 
protein content (e.g. urine or sweat), the sample is often only diluted prior to 
analysis.65 For samples with a high protein content (e.g. serum, plasma, 
tissue), PPT with organic solvent is commonly used, which at the same time 
enables extraction of a wide range of various metabolites.69,75,78 Sample 
extraction and purification with LLE or SPE is often also necessary to remove 
matrix interferences and concentrate the analytes. Derivatization is often 
required in GC-MS applications and sometimes in LC-MS to enhance the 
ionization efficiency or to increase retention to the LC column.79–81  
Evaporation and reconstitution are often the last steps and are used to 
concentrate analytes or change the solvent to one compatible with the analysis 
method, although analyte solubility and potential oxidation should be 
considered. 
1.3.3.1 Extraction and protein precipitation 
 
Extraction and PPT with solvents such as MeOH, ACN, ethanol (EtOH), 
isopropanol (IPA), acetone, or a mixture of these with water or each other is 
the most commonly applied sample pretreatment protocol in non-targeted 
metabolomics.17,75,78,82–84  Although PPT approaches have been evaluated  in 
terms of protein-removal efficiency, metabolite coverage, precision, 
repeatability, stability, and extraction recovery in several studies, there is 
currently no general consensus of the best PPT approach in 
metabolomics.78,82,85 Alternative procedures for removing proteins are 
ultrafiltration and turbulent flow chromatography.86,87 Thus far, both of these 
methods have shown poor metabolite recoveries in comparison with solvent-
based methods.86,87  
The selection of sample extraction solvent depends significantly on the 
polar range of the analytes to be extracted. Figure 4 shows which kinds of 
metabolites can be extracted with commonly used solvent systems in 
metabolomics. For the extraction of highly polar metabolites (left side in 
Figure 4), additional water is essential. In contrast, addition of non-polar 
solvent (e.g. chloroform) is required for the extraction of non-polar lipids such 
as triacylglycerols (Figure 4). Addition of chloroform or another non-polar 
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solvent with a certain solvent ratio forms a two-phasic LLE system, where two 
solvent layers are immiscible with each other. LLE is widely utilized in non-
targeted lipidomics applications as well to simultaneously extract the polar 
(metabolites) and non-polar (lipid) fractions.17,75,88 The most popular LLE 
methods in lipidomics are extractions with chloroform-MeOH mixtures such 
as Folch extraction,89 Bligh and Dyer,90 or extraction with methyl-tert-butyl 
ether (MTBE)/MeOH mixture, referred to as the Matyash method.91 
Furthermore, modifications of these with different solvent ratios are 
popular.92,93 Additionally, a two-phase extraction, for example with 
MeOH/chloroform/MTBE mixture,94 dichloromethane/MeOH mixture,95 or 
two-step extraction with butanol/MeOH followed by heptane/ethyl 
acetate/acetic acid have been applied in lipidomics.96 In some studies, a single 
extraction protocol (chloroform/MeOH or MTBE/MeOH) has been used to 
collect both layers of biphasic extraction, with the lipophilic solvent containing 
non-polar compounds and the hydrophilic solvent containing polar 
compounds.88 The benefit of two-phase extraction is the wider metabolite 
coverage from the same sample. However, medium polar compounds are 
distributed to both phases. LLE can also be performed as a two-step extraction 
protocol by extracting first polar compounds followed by lipid extraction from 
the same samples.97 Subsequent supernatants can be analyzed separately or, 
alternatively, the polar and non-polar fraction can be pooled into one 
sample.98 
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Figure 4 Predicted octanol/water partition coefficient (XlogP) ranges of common metabolite 
classes detected in blood plasma (top), polarity ranges of isolated metabolites with typical solvents 
or solvent mixtures used in metabolomics and lipidomics (middle), and polarity indexes of solvents 
in sample extraction (bottom). Cer, ceramides; Chol, cholesterol; CholE, cholesteryl esters; CL, 
cardiolipins; DG, diacylglycerols; FAHFA, fatty acid esters of hydroxyl fatty acids; LPA, 
lysophosphatidic acids; LPC, lysophosphatidylcholines; LPE, lysophosphatidylethanolamines; MG, 
monoacylglycerols; PA, phosphatidic acids; PC, phosphatidylcholines; PE, 
phosphatidylethanolamines; PG, phosphatidylglycerols; PI, phosphatidylinositols; PS, 
phosphatidylserines; PUR, purines; PYR, pyrimidines; SM, sphingomyelins; TG, triacylglycerols; 
TMAO, trimethylamine N-oxide. Reprinted with permission from 17. Copyright 2019 American 
Chemical Society.  
1.3.3.2 Solid-phase extraction and solid-phase micro extraction 
 
SPE has high selectivity but often at the cost of metabolite coverage. SPE is 
thus less frequently used in non-targeted metabolomics than solvent-based 
extraction methods.99 SPE is also often more time consuming and the 
extracti0n protocol and method optimization can be more complex due to the 
unique selectivities of SPE sorbent materials.99,100 SPE has often been applied 
in non-targeted metabolomics and lipidomics for desalting and concentrating 
urine samples,101–103 for removing phospholipids or acylglycerides to enhance 
sensitivity of other analytes,104–108 or fractioning of the sample to smaller 
subsets of analytes.109–111 Although metabolomics analysis using SPE 
fractionation is time consuming, the method provides detection of a higher 
number of metabolites, improved chromatographic separation, and reduced 
ion suppression in MS analysis.110 Several different sorbent materials (i.e. 
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modified silica, graphite, polymer, and zirconium) with different column 
chemistries such as C18, HILIC, mixed-mode, and ion exchange have been 
studied in non-targeted metabolomics applications.101–103,109–111 Mixed-mode 
cartridges with multiple interaction mechanisms in the cartridge have been 
shown to be suitable for a wide range of metabolites.101,102 C18 also provides 
universal material for a large range of metabolites,101 but the retention of many 
highly polar compounds may be poor. SPE is especially useful in targeted 
methods where the high sensitivity and selectivity is desired. For example, SPE 
has been applied for the analysis of purines and pyrimides,112 bioactive 
lipids,113 neurotransmitters,114 and bile acids.106 Although the SPE protocol can 
be quite slow, it can also be completely automated (e.g. online-SPE) or 
multiple samples can be extracted simultaneously using a 96-well format.100,111   
Solid-phase micro extraction (SPME) has been used in metabolomics 
primarily to extract volatile and semi-volatile metabolites, such as food flavors 
and aromas, human breath, or skin biomarkers.115,116 SPME is less frequently 
used to extract non-volatile metabolites, such as lipids or amino acids in 
biofluids.115,116 For example, SPME has been utilized to study emissions of 
volatile metabolites during stem cell differentiation,117 volatiles from 
pathogens,118 and cellular metabolites from E. coli.119 
1.3.3.3 Derivatization 
 
Derivatization is required for polar metabolites prior to GC-MS analysis to 
increase volatility, thermal stability, and chromatographic mobility; to 
improve chromatographic peak shape; and to reduce peak tailing.60 
Derivatization can also add desired diagnostic fragments to mass spectra for 
identification purposes.60 Carboxylic acids, alcohols, amines, and thiols can be 
derivatized by alkylation, acylation, or silylation.60,79 The most commonly 
applied derivatization prior to GC-MS analysis of metabolites is silylation with 
trimethylsilyl (TMS) reagents. N-Trimethylsilyl-N-methyl trifluoroacetamide 
(MSTFA) and N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA) are the 
most popular silylation reagents in metabolomics, although other reagents are 
available as well.60,63 In some cases, addition of trimethylchlorosilane (TMCS) 
as a catalyst to silylation reaction, use of pyridine as a solvent, and heating can 
be used to accelerate the derivatization with MSTFA or BSTFA.120 In non-
targeted metabolomics, the most popular protocol prior to GC-MS analysis is 
two-step derivatization with oximation usually with a methoxyamine (MOX) 
followed by silylation.63,66 The MOX protects carbonyl moieties and prevents 
formation of multiple reaction products during silylation.121 As the silylation 
reagent and the derivatized extracts are sensitive for hydrolysis, the presence 
of water in the silylation reaction mixture must be avoided in all phases of 
sample treatment.79 
Different techniques, such as offline derivatization,122 microwave-assisted 
derivatization,123 in-time,66 and injection-port derivatization124 can be applied 
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in the derivatization process. Offline derivatization is currently the most 
applied approach, where derivatization is performed simultaneously on all 
samples in a batch and analysis is recommenned to be completed within 24-
48 h after the derivatization.122,125 Microwave-assisted derivatization is used to 
reduce the derivatization time to just a few minutes.123 In-time derivatization 
is performed by robotics just before injection into GC. Samples are not exposed 
to degradation during storage on a sample tray prior to injection as in offline 
derivatization.66  
Chemical derivatization can also be applied prior to LC-MS or direct 
infusion analysis to increase ionization efficacy in electrospray (ESI) 
ionization of poorly ionizable or non-ionizable compounds, such as neutral 
alcohols, phenols, and some steroids.80,126,127 Derivatization can also improve 
the retention of highly polar compounds to a reversed phase LC column that 
decreases matrix effects in the LC-MS analysis.126,127 For example, the 
derivatization of carboxylic acids in the tricarboxylic acid (TCA) cycle,128 
amino acids,129 neurotransmitters,130 phospholipids,131 and steroids prior to 
ESI-LC-MS analysis have been used in targeted metabolomics.80,132 Multiple 
derivatization reagents can be used depending on the derivatized functional 
group or the application. For example, o-benzylhydroxyl amine for 
derivatizing carboxylic acids ,128 hydroxylamine for ketones,132 and dansyl 
chloride for aliphatic alcohols, phenols, and amines have been applied in 
targeted metabolomics.126,127,130  
1.3.4 MASS SPECTROMETRY 
1.3.4.1 Ionization methods 
 
The most common ionization methods in LC-MS and direct infusion mass 
spectrometry (DI-MS) are electrospray ionization (ESI), atmospheric pressure 
chemical ionization (APCI), and atmospheric pressure photoionization 
(APPI).133 ESI is the most popular and widely applied ionization technique in 
metabolomics.20,104,134,135 ESI is a soft ionization method suitable for analysis 
of a wide range of small and large molecules. ESI provides good ionization 
efficiency for medium polar, polar, and ionic compounds. These compounds 
are normally ionized via protonation, deprotonation, cation, or anion 
attachment (i.e. adduct formation). However, the ionization efficacy in ESI 
towards non-polar neutral compounds may be poor. ESI is also prone to ion 
suppression that may disturb quantitation of metabolites. Although APCI or 
APPI are still used quite rarely in metabolomics, APCI and APPI are more 
applicable for small to medium weight non-polar and polar compounds.136–139 
In particular, APPI has shown high sensitivity towards non-polar lipids, such 
as steroids.140–142 Other ionization techniques such as matrix-assisted laser 
desorption ionization (MALDI), secondary ion mass spectrometry (SIMS), 
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and various ambient MS methods have also been utilized in metabolomics and 
MS imaging of metabolites.143–146   
The two main ionization methods in GC-MS are vacuum techniques, 
specifically electron ionization (EI)60,66 and chemical ionization (CI).60,147 
Typically EI with commonly applied 70 eV electrons results in extensive, 
characteristic fragmentation and the spectra can be searched against widely 
available EI-MS spectral libraries for identification. However, the 
fragmentation decreases sensitivity and selectivity and may eliminate the 
formation of molecular ions, which are important for identification of analytes. 
CI provides softer ionization and causes less fragmentation than EI. Usually in 
CI protonated or deprotonated ions are also formed allowing determination of 
molecular mass. However, CI is not commonly used in metabolomics. GC can 
also be connected to MS by using API methods, such as APCI,148,149 
APPI,142,149,150, and ESI.149,151 In API sources, abundant molecular ions or 
protonated or deprotonated molecules are formed, which can be further 
fragmented selectively by MS/MS. When using atmospheric pressure 
ionization (API) sources, both GC and LC can be connected to the same mass 
spectrometer equipped with an atmospheric pressure to vacuum ion optics, 
without the need for separate expensive mass spectrometers. However, the 
disadvantage of all API techniques is that significant numbers of ions are lost 
in the ion transfer from atmospheric pressure to the vacuum of MS.152 Ion 
transmission in photoionization has been improved with systems in which the 
photoionization occurs inside a transfer capillary between the atmospheric 
pressure and vacuum.153–155 These systems have shown high sensitivity 
towards non-polar compounds when applied as an interface in GC-MS or DI-
MS.153–155 
1.3.4.2 Mass analyzers 
 
Various mass analyzers have different applicable acquisition speeds, mass 
resolution, mass accuracy, mass range, dynamic range, and scan modes, which 
should be considered when selecting a suitable metabolomics method. Mass 
analyzers can be divided into high-resolution instruments measuring accurate 
mass such as time-of-flight (TOF), Fourier transform ion cyclotron resonance 
(FT-ICR), and Orbitrap, or to unit resolution mass analyzers such as 
quadrupole (Q) or ion trap (IT).11,17 Some of these analyzers (FT-ICR and IT) 
are capable for tandem mass spectrometry (MS/MS or MSn) and selective 
fragmentation of selected precursor ions. Mass spectrometers can be also 
hybrid instruments, containing two or more mass analyzers also capable for 
MS/MS analysis. Hybrid instruments, such as Q-TOF, triple quadrupole 
(QQQ), and IT-Orbitrap are widely applied in metabolomics.11,17 The most 
common collision cells for fragmentation in MS/MS measurements are 
collision-induced dissociation (CID) and higher energy collision dissociation 
(HCD), which is a CID-type collision cell available in Orbitrap. Additionally, 
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ultraviolet photodissociation (UVPD), which reveals the double bond locations 
of complex lipids, has been applied but with less frequently.156,157 High-
resolution mass spectrometers (HRMS) are often used in non-targeted 
analysis,11,17,58 whereas QQQ using multiple reaction monitoring (MRM) scans 
are more frequently utilized in targeted analysis.19,20,23  
In non-targeted metabolomics, typically an MS full scan is first recorded 
and additional targeted MS/MS analysis is performed based on the precursor 
ions of interest. Different improvements in HRMS analyzers and software have 
enabled enhanced acquisition rates and made it possible to collect several 
MS/MS experiments within a single run in addition to the MS scan.158 These 
methods are data-dependent acquisition (DDA) and data-independent 
acquisition (DIA).159,160 In data-dependent methods, MS/MS acquisition can 
be triggered with an intensity threshold or by applying inclusion and exclusion 
lists or other set thresholds.161 However, the number of produced spectra and 
the spectral quality is limited. DIA instead aims to fragment and collect 
MS/MS-spectra from all precursor ions and acquisition is not affected by the 
acquired data.160 One DIA method is sequential window acquisition of all 
theoretical fragment-ion spectra (SWATH), which fragments all precursor 
ions within defined a RT and precursor m/z window.162 More traditional 
precursor ion scans (PIS) or neutral loss scans (NLS) with QQQ to detect a 
certain compound class are commonly applied in non-targeted or semi-
targeted lipidomics.13 
1.3.5 GAS CHROMATOGRAPHY-MASS SPECTROMETRY 
 
Gas chromatography-mass spectrometry (GC-MS) is a widely applied 
method in metabolomics and is suitable for analysis of volatile and thermally 
stable low-molecular weight (MW <600 Da) compounds.60 GC-MS is efficient, 
robust, sensitive, selective, reproducible, and has good resolution in 
separation. GC-MS does not suffer as much from common drawbacks such as 
matrix effects and ion suppression encountered in LC-MS. The separation 
system is quite simple with only one mobile phase. Separation is based mainly 
on evaporation in the order of boiling point with influence from analyte 
interactions with the column. Separation and sample pretreatment in GC-MS 
may be time consuming and GC-MS is not suitable for non-volatile higher 
molecular weight biomolecules, such as many lipids and peptides. The most 
common procedure in GC-MS is extraction of a metabolomics sample followed 
by chemical derivatization, which is required especially for polar or non-
volatile metabolites with poor thermal stability.79 Thus far, GC-MS methods 
with unit resolution are most commonly used in non-targeted and targeted 
analysis.60 Identification in non-targeted (and targeted) analysis is typically 
based on characteristic EI-MS spectra that can be searched against broad 
spectral libraries. In targeted methods, MS/MS with a QQQ is also frequently 
used, which provides excellent selectivity and sensitivity in monitoring of 
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metabolites.142,163 However, HR instruments are becoming more popular in 
metabolomics, with the ability to measure accurate mass and define the 
elemental formula.164,165 GC-MS has often been applied for non-targeted 
analysis of metabolites such as amino acids, organic acids, and fatty acids after 
derivatization.60,66 
GCxGC-MS is also a widely used technique in metabolomics due to its high 
resolving power in separation.66,166 The first dimension commonly utilizes a 
non-polar 5% diphenyl- and 95% dimethyl-polysiloxane column and the 
second dimension is a short polar column after modulation.66 The separation 
in the second dimension lasts only some seconds.66 Data processing and peak 
picking are challenges, however, the separation and spectral purity are 
improved without a significant increase in the analysis time. 
1.3.6 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY 
 
Liquid chromatography-mass spectrometry (LC-MS) is the major 
analytical technology in global metabolomics due to its high sensitivity, 
repeatability, and wide coverage of metabolites with diverse chemical 
properties.167 Ultra-high pressure liquid chromatography (UHPLC) has 
replaced traditional high-pressure LC instruments (HPLC) in metabolomics 
due to improved peak capacity, sensitivity, and faster analysis.167,168 Sensitivity 
and peak capacity can be improved even further with nano- or capillary-
UHPLC. Nano- and capillary-LC combined with nano-ESI offers improved 
chromatographic resolution and sensitivity and is especially suitable for low-
volume metabolomics samples.102,169 However, the analysis time increases 
markedly with lower flow rates and thus nano- and capillary-LC are less 
frequently used in metabolomics.102 The most widely applied tool in 
metabolomics is reversed-phase (RP) chromatography with C18 column and 
gradient elution, which is highly suitable for a large range of metabolites.167 
Other columns such as C8 or C30 are also applied but less frequently.170,171 
However, highly polar and ionic compounds do not have adequate retention 
on RP materials and these compounds elute in the void volume. This increases 
the need for other column chemistries, such as hydrophilic interaction 
chromatography (HILIC) or normal phase (NP) chromatography.172–174 
Commonly used NP solvents, such as hexane and heptane, are poorly suitable 
for the ESI ionization technique typically applied in LC-MS, which is why NP 
is rarely used in metabolomics. This has made HILIC an attractive alternative, 
as it offers a contrary elution order to RP with common organic solvents (such 
as ACN and MeOH) and increases elution strength with increasing water 
content.172,173 HILIC is nowadays often applied in targeted and in non-targeted 
metabolomics to detect polar metabolites.22,170,172,173,175,176 The disadvantages 
in HILIC are the long re-equilibrium times and poor repeatability of retention 
times.167,172 Some highly polar ionic compounds may have better retention 
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with ion chromatography or ion-pair chromatography using an RP 
column.177,178  
Lipids can be separated with NP or HILIC based on their polar head group, 
which separates lipid classes,136,179 whereas RPLC separates lipids based on 
polar head group and number of carbon and double bonds in the fatty acid 
alkyl chains of lipids.12 These two main lipidomic approaches can also be 
combined into a two-dimensional (2D) separation.136,180 2D-LC-MS systems 
have been used to some extent and have used HILIC and C18 colums for the 
simultaneous analysis of polar metabolites and lipids.136,181,182 In 
comprehensive 2D-LC (e.g. LCxLC), the whole effluent from the first 
dimension is transferred into the second dimension, using a dedicated 
switching valve and running ultrashort gradients. In heart-cutting 2D-LC,182 
only one or two fractions from the first dimension effluent are transferred into 
the second dimension with longer gradients than in comprehensive 2D-LC.181 
Although 2D systems increase peak capacity and selectivity, the analysis time 
and complexity of data processing limits the application of these systems in 
metabolomics.181 
1.3.7 DIRECT INFUSION AND MICROCHIP METHODS 
 
Direct infusion (DI) of crude metabolite extracts to MS shows great potential 
due to its wide metabolite coverage, high throughput, and simple and rapid 
analysis.183 However, DI-MS can suffer from extensive ion suppression and the 
inability to separate isobaric and isomeric substances. DI metabolite analysis 
is usually performed using a syringe pump or a chip-based nano-ESI source 
(Nanomate) that constantly delivers the sample.13,135,183,184 Several other 
microchip-based methods than commercial Nanomate have also been 
proposed for the direct analysis of metabolites.185,186 Alternatively, the sample 
can be injected with a LC autosampler as a plug to constant solvent flow (i.e. 
flow injection analysis [FIA]).135,187 Since no chromatographic separation is 
used in DI or FIA analysis, HRMS is commonly used to improve peak capacity 
in non-targeted metabolomics.135,183 MS/MS methods have been commonly 
used in targeted DI or FIA metabolomics analysis.183 Even commercially 
available kits for quantifying metabolites from different compound classes are 
available.188 DI- or FIA-MS/MS is most commonly used in lipidomics (i.e 
shotgun lipidomics) utilizing several experimental conditions and PIS and 
NLS for selectively ionizing different lipid subgroups at a time.13,184 
Ambient MS techniques, in which metabolites are directly analyzed from 
biological samples without the necessity for sample pretreatment, can be 
considered as a special kind of DI-MS method.144,146,189,190 The most commonly 
applied ambient techniques in metabolomics are desorption electrospray 
(DESI) and direct analysis in real time (DART), which are utilized especially 
in tissue imaging applications in addition to MALDI-MS and SIMS.143–146,189–
191 
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1.3.8 OTHER METHODS 
 
Capillary electrophoresis-mass spectrometry (CE-MS) is suitable for 
analysis of ionic compounds, which are separated based to their charge-to-size 
ratio.59,61 CE-MS is especially suitable for amino acids, small peptides, 
nucleosides, nucleotides, sugar phosphates, organic acids, and sulfated 
compounds, which can be challenging in LC-MS analysis.59,61,192 CE-MS has 
high sensitivity, selectivity, has the potential for large-scale metabolic 
profiling, and is suitable for low-volume samples down to sub-cellular 
volumes. 59,61,193 CE-MS suffers from variable migration times, technical 
challenges in coupling CE to MS, and lack of standard methodologies.59,61 
However, a recent cohort study applying CE-MS showed good reproducibility 
and suitability for large-scale studies.194  
Ion-mobility spectrometry (IMS) separates ions in the gas phase based on 
their mobility in a carrier buffer gas when they travel through the ion mobility 
separation cell under an electric field.195 The drift time is the time required for 
an ion to travel through the cell, which again depends on ion properties such 
as charge, shape, and size.195–198 The separation is rapid, with drift times at the 
millisecond scale. Another advantage is that the collision cross section (CCS) 
values derived from the drift times represent a physicochemical property that 
can be applied in the identification of metabolites or lipids.195–198 IMS 
combined to MS (IMS-MS) provides a very rapid and relatively selective 
analysis and is increasingly applied in metabolomics and especially in 
lipidomics.195 IMS has also been combined to LC-MS systems to improve peak 
capacity, signal-to-noise, and purity of MS/MS spectra.195,199,200 CCS structural 
databases and libraries, commercially available instruments, improvments in 
separation resolution, and the available preprocessing tools will increase the 
usage of IMS in the future.195–198,201  
Supercritical fluid chromatography-mass spectrometry (SFC-MS) is less 
frequently applied but offers the possibility for complementary separation 
with properties combining GC and LC.202 SFC-MS has been applied in lipid 
profiling and in targeted methods.203,204 A comparison of SFC-MS with HILIC 
LC-MS and DI-MS for lipidomics demonstrated that SFC-MS has excellent 
sensitivity for less polar lipid classes and high sample throughput and the SFC-
MS method is applicable for lipidomics of biological samples.202  
1.3.9 DATA PREPROCESSING AND ANALYSIS 
1.3.9.1 Data preprocessing 
 
Data processing and peak integration is straightforward and routine in 
targeted metabolomics and instrument vendor programs are commonly 
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applied. Non-targeted metabolic raw data can be preprocessed with 
commercial instrument vendor software, such as MassProfiler (Agilent), 
MetaboScape (Bruker), Chromatof (LEGO), MarkerView (SCIEX), Compound 
Discoverer (Thermo Fisher), and Markerlynx (Waters). These programs are 
easy to use, well tested, and documented. However, these are commonly fixed 
for only a certain data format, the applied algorithms are nontransparent, and 
the software can be expensive. Open-source programs are instrument-
independent, freely available, allow modifications, and the functions are 
usually more transparent. The most commonly applied open-source tools for 
metabolomics MS data  preprocessing are XCMS,205 MzMine2,206 OpenMS,207 
MetaboAnalyst,208 MSDial,209 Workflow4metabolomics,210 Galaxy 
workflow,211 MetAlign,212  and AMDIS,213 among multiple others available.214 
Many of these open-source online platforms include data pre-processing, post-
processing, and data analysis steps and are suitable for GC-MS, LC-MS, and 
DI-MS data. Raw data conversion for common open data formats (mzXML, 
mzML, netCDF) may be necessary before applying open-source tools. Data can 
be converted typically with instrument software or the freely available 
proteowizard.215 Preprocessing steps aim to reduce the data complexity and 
noise and to select the metabolic signals to create a data matrix for further data 
analysis. The data pre- and post-processing pipeline commonly includes noise 
filtering, baseline correction, peak picking, peak deconvolution, alignment, 
filtering, normalization, scaling, annotation, and identification. Several 
algorithms can be applied in these steps and not all are mandatory.214,216 Two-
dimensional separations (i.e. GCxGC and 2D-LC) and IMS-MS applications 
requires certain chemometrics and data preprocessing algorithms.201,217,218 
1.3.9.2 Metabolite identification 
 
The non-targeted workflow in metabolomics usually contains HRMS 
analysis, feature detection, and data analysis, followed by identification of 
interesting and relevant metabolic features with MS/MS.158 With modern 
instruments, MS/MS data can also currently be collected simultaneously with 
DDA and DIA modes.158 Metabolite identification is the most time-consuming 
step and is a bottleneck in metabolomics. Metabolite identification can be 
classified to different classes (Level 1-4.) based to their identification 
confidence.219 Level 1 corresponds identification against authentic chemical 
standards, level 2 corresponds to putative annotation and identification 
against MS/MS spectral databases. Level 3 is characterized compound class 
and Level 4 is an unknown feature with a unique mass-to-charge ratio and 
possible additional retention time.   
For identification purposes of LC-MS or DI-MS data, multiple online 
databases are available for tentative level-3 identification with molecular 
mass, including METLIN,220 Human metabolite database (HMDB),221 Kyoto 
encyclopedia of genes and genomes (KEGG),222 Lipid Maps,223 and 
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DrugBank.224 With MS scan and accurate mass measurements by HRMS, the 
identification of metabolites is based on the molecular weight of diagnostic 
ions. In addition to retention time in GC- and LC-MS analysis, isotope 
abundancies and possible adduct ions may provide additional information for 
identification. MS/MS spectra provide additional structure information of the 
detected feature. Measured MS/MS spectra can be searched against 
commercial spectral databases (NIST 14, MetaboBASE), open-source 
databases (HMDB,221 METLIN,220 MassBank,225 mzCloud 
(https://www.mzcloud.org/), the Global Natural Product Social Molecular 
Networking [GNPS],226 MassBank of North America [MoNA] 
(http://mona.fiehnlab.ucdavis.edu/)), and others.227,228 However, the 
measured MS/MS spectra are not always comparable against the MS/MS 
spectra libraries due to different MS/MS istruments and collision conditions 
used in the measurements. Furthermore, the metabolite coverage in spectral 
libraries is limited. Therefore, other tools such as MS/MS in-silico 
fragmentation and prediction tools commercially available (Mass Frontier, 
MyCompound ID) or open-source (MS-FINDER,229 SIRIUS,230 MAGMa,231 
CFM-ID,232 MetFrag,233 CSI:FingerID,234 and LipidBlast235) have been 
developed. These tools utilize existing structure and chemical databases and 
generates mass spectra computationally based on quantum chemistry, 
machine learning, chemical reactions, or heuristic-based approaches.236 The 
performance of different in-silico tools have been recently studied in the 
Critical Assessment of Small Molecule Identification (CASMI) challenge.237,238  
Identification is usually more straightforward in GC-MS as identification is 
based on highly repeatable available EI spectral databases and relative 
retention indexes (RI).239 The most applied EI libraries are NIST 14, Wiley, 
Golm Metabolome Database (GMD),240 and Fiehn library,241 where the 
measured EI-MS spectrum and RI are compared to reference data using a 
similarity score algorithm (e.g. dot product).242 The GMD provides additional 
information on the predicted functional groups in a compound, based on 
supervised machine learning from previously analyzed spectra and RI 
values.243 GC-HRMS is currently used with increasing frequency and accurate 
mass fragments can be used in the identification.244 
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1.3.9.3 Data and pathway analysis 
 
Data analysis in metabolomics commonly includes different statistical and 
multivariate data analysis methods, which are performed on the data matrix 
after pre-processing.245–247 Some post-processing steps, such as scaling (i.e. 
variance scaling, transferring to logarithmic scale) and imputing missing 
values, are usually performed prior to data analysis.245 An unsupervised 
principal component analysis (PCA) is generally used as an initial data mining 
and classification method to observe possible differences between sample 
groups.247 Supervised  classification techniques, such as partial least squares-
discriminant analysis (PLS-DA), orthogonal partial least squares-discriminant 
analysis (OPLS-DA), support vector machines, random forests, and other 
neural network methods, are also often applied.247 Clustering is typically 
applied to study relationships and the similarity of samples or metabolites, or 
both. The most popular clustering methods in metabolomics are hierarchical 
and K-means clustering.246,247 A receiver operating characteristic (ROC) curve 
is commonly utilized for biomarker modeling and to estimate biomarker 
prediction power. Different regression models are used to study variable 
dependencies.246,247  
Univariate statistics are commonly applied in metabolomics with 
parametric tests (unpaired or paired t-test and analysis of variance [ANOVA]) 
or non-parametric tests (Mann-Whitney U-test, Wilcoxon signed-rank test, 
and Kruskal-Wallis test) depending on the application.245,246 In metabolomics, 
the parallel univariate tests exceeds the number of observations, which highly 
increases the number of false positives. This multiple testing problem is 
commonly corrected with false discovery rate (FDR) correction or with 
Bonferroni correction.245  
In addition to metabolite levels, metabolic reactions and pathways are also 
important especially in mechanistic studies.248 Metabolite pathway analysis is 
commonly enrichment analysis, which computes significantly altered 
metabolic pathways, or metabolite mapping, which contextualizes the 
abundances and significances of measured metabolites into network 
visualizations.248 Commonly utilized tools and databases for metabolite 
pathway analysis include  KEGG pathways,222 MetaboAnalyst,208 small 
molecule pathway database (SMPDB),249 Reactome,250 and MetaCyc251. 
Pathway analysis is limited only to the identified compounds, which prevents 
a deeper understanding of metabolism in multiple studies. New analysis 
modes (i.e SWATH, DDA, DIA) and the improvement of identification tools 
will likely shift identification towards all detected metabolites, not only to 
possible biomarkers. 
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2 AIMS OF THE STUDY 
The overall aim of this study was to apply and develop mass spectrometry-
based analytical methods for metabolomics. The goal was to develop non-
targeted methods for screening metabolic changes between different 
biological conditions (publications I-III). The required analysis times in these 
non-targeted screening methods with chromatographic separation were quite 
long and thus prevented high-throughput analysis. To reduce the analysis 
time, non-targeted chip-MS analysis was studied to detect differences in cell 
metabolites (publication III). The sensitivity of non-targeted metabolomics is 
limited and depends on the metabolite chemical properties. Due to low 
ionization efficacy in ESI and high fragmentation in EI, non-polar low 
abundant metabolites (such as steroids) are usually not detected with common 
non-targeted screening methods. The CPI source developed in-house provides 
high sensitivity towards non-polar metabolites and its feasibility and 
utilization in metabolomics studies were explored (publications IV and V). 
 
The more detailed aims of the research papers presented in this thesis were as 
follows: 
 
• To study the metabolic differences in neonatal mouse hearts that reflect 
changes in the regeneration capacity of cardiomyocytes (I) 
 
• To study the human serum metabolite profile associated with insulin 
resistance and gut microbiota of non-diabetic individuals  (II) 
 
• To evaluate the suitability of the microchip-based direct infusion mass 
spectrometry for non-targeted analysis to study stem cell metabolites 
and to compare the performance to the most often applied UHPLC-ESI-
QTOF-MS method (III) 
 
• To develop a CPI ion source to increase sensitivity and to develop a GC-
CPI-MS/MS method to evaluate CPI performance for the analysis of 
endogenous steroids from a biological matrix (IV) 
 
• To test the feasibility of the CPI method coupled with LC-MS and low 
flow rates to analyze selected steroids (V) 
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3 EXPERIMENTAL  
This section briefly describes the chemicals, samples, instruments, and 
analytical protocols used in this study. More detailed descriptions can be 
found from the original publications I-V.  
3.1 CHEMICALS AND MATERIALS 
All chemicals used in this study (I-V) were analytical or chromatographic 
grade. More detailed information and the material and chemical suppliers are 
available in the original publications (I-V).  
3.2 SAMPLES AND SAMPLE PRETREATMENT 
3.2.1 MOUSE HEART SAMPLES  
 
Mouse pups (strain C57BL, n=92, publication I) were acquired from the 
experimental animal facility of the University of Helsinki with an internal use 
licence (KEK14-014). Heart tissue samples were collected on postnatal days 1, 
4, 9, and 23 (P01, P04, P09, and P23, respectively) at midday without fasting 
and before weaning. Mice were decapitated, ventricles were excised and cut 
into three to five pieces, rinsed in PBS, snap-frozen in liquid nitrogen, and 
stored at -80°C prior to sample pre-treatment.  
The tissue samples were homogenized in water using a probe sonicator 
(sample set 1) or FastPrep-24 5G bead homogenizer with 1-mm zirconia beads 
(sample set 2). For GCxGC-MS analysis, 25 μL of homogenate and 410 μL 
MeOH containing labeled internal standards (ISTD) were transferred into an 
Eppendorf tube. The samples were vortexed, sonicated for 5 min, and 
incubated on ice for 30 min, after which the extracts were centrifuged for 5 
min (14 338 g, 4°C) and 180-μL aliquots of supernatants were transferred into 
vials and evaporated to dryness under a nitrogen flow. The metabolites were 
then derivatized by automated two-step in-time derivatization. First, 25 μL of 
MOX was added to the residue and the mixture was incubated for 1 h at 45 °C. 
Next, 25 μL of MSTFA including the RI standards was added and the mixture 
was incubated for 1 h at 45 °C. Finally, hexane including injection standard (50 
μL) was added to the mixture immediately prior to injection. QC samples were 
prepared by pooling P4, P9, and P23 tissue sample homogenates and were 
otherwise prepared similarly as the samples. All the samples were randomized 
before sample pretreatment and analysis.  
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For LC-MS analysis, 25 μL of the sample homogenate, 5 μL of ISTD 
mixture, and 100 μL of MeOH were transferred into an Eppendorf tube 
followed by vortexing and incubation on ice for 30 min. The samples were then 
centrifuged for 10 min (7 378 g) and the supernatants were transferred into 
vials and analyzed in randomized order with additional QC, standard, and 
blank samples. 
3.2.2 HUMAN SERUM SAMPLES  
 
Human serum samples (n=397, publication II) were collected as part of the 
Danish MetaHIT consortium (http://www.metahit.eu) from Danish 
participants, including normoglycaemic and middle-aged individuals (n=291), 
type 2 diabetes patients (n=75), and type 1 diabetes patients (n=31). The study 
was approved by the Ethical Committees of the Capital Region of Denmark 
(HC-2008-017 and H-15000306) and was in accordance with the principles of 
the Declaration of Helsinki. All individuals provided written informed consent 
before participating in the study. Serum samples were collected in the morning 
after an overnight fast of at least 10 h and without prior morning physical 
activity using the same personnel and protocol for all the samples. Serum 
lipids were extracted with modified Folch extraction by mixing 10 μL serum, 
20 μL of ISTD mixture, and 100 μL of chloroform:MeOH (2:1, v v-1). The 
mixture was vortexed for 2 min, incubated at room temperature for 30 min, 
centrifuged for 3 min (7800 g), followed by the collection of the lower phase 
(60 μL) and addition of second ISTD mixture (20 μL). Extracted samples were 
stored at -20°C prior to analysis. Sample pretreatment and analysis order were 
randomized and control serum samples, extracted standard samples, pure 
standard samples, and blanks were analyzed together with the human serum 
samples. 
3.2.3 CELL SAMPLES  
 
Human foreskin fibroblasts (HFF) and human induced pluripotent stem 
cells (hiPSC) (publication III) were grown at the Institute of Biotechnology in 
the University of Helsinki. hiPSC cell line HEL24.3 was differentiated from 
HFF using non-integrative Sendai virus-mediated transduction with Oct4, 
Sox2, Klf4, and c-Myc as described earlier.252 Six replicates of HFF (1 x 106 
cells), HiPSC (5 x 106 cells), and blanks were analyzed. Cells were washed with 
PBS, snap-frozen in liquid nitrogen, and stored in -80°C prior the analysis. 
 Cells were lysed by adding 50 μL of MilliQ water (MQ) to the frozen cell 
pellet and sonicated in an ice-cold ultrasound bath for 15 min two times with 
mixing between the cycles. Next, 20 μL of the cell lysate, 10 μL of ISTD 
mixture, and 100 μL of MeOH was mixed. The cell extract was then vortexed 
and incubated on ice for 20 min. After incubation, the extract was centrifuged 
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for 10 min (7378 g) and the supernatant was transferred into a vial and stored 
at -20 °C until analysis. For LC-MS, the samples were injected as such. For 
chip-MS, 10% formic acid (FA) in MQ water was added to the samples to 
achieve a final solvent composition of 70:29:1 (MeOH:H2O:FA). 
3.2.4 HUMAN URINE SAMPLES 
 
Urine samples (publication IV) were collected from four male and four 
female volunteers. Each authentic sample was divided into two aliquots; one 
aliquot was used to determine free steroids and the other aliquot was used to 
analyze the sum concentrations of steroid glucuronide conjugates and free 
forms. The glucuronide-conjugated steroids were hydrolyzed before extraction 
by adding 0.8 M sodium dihydrogen phosphate solution (1 mL, pH 7) and 
glucuronidase (50 μL) followed by incubation at 50°C for 1.5 hours. After 
enzymatic hydrolysis, steroids were extracted and derivatized similarly as the 
free steroid fraction of urine and artificial urine samples. 
17α-methyltestosterone was used as an ISTD with a final concentration of 
10 ng mL-1. The sample (2.5 mL) pH was adjusted to approximately pH 8 by 
dissolving NaHCO3/K2CO3 (125 mg, 2:1, w w-1) mixture in each sample. After 
pH adjustment, steroids were extracted with LLE to diethyl ether. Diethyl 
ether (4 mL) and Na2SO4 (1.5 g) were added to samples followed by vortexing 
and centrifugation (2000 g) for 10 min. Part of the organic phase (2.5 mL) was 
transferred into a new test tube and evaporated to dryness under nitrogen 
flow. The derivatization reagent mixture MSTFA/NH4I/DTE (50 μL, 
1000:2:4, v w-1 w-1) was added to the tube, vortexed, and the sample was 
transferred to a GC vial. The sample was incubated at 60°C for 15 min to 
derivatize all hydroxyl and keto groups of steroids with TMS. After offline-
derivatization, samples were ready for injection into GC. 
 
3.3 INSTRUMENTATION, ANALYTICAL METHODS, AND 
DATA PROCESSING 
3.3.1 GLOBAL METABOLOMICS OF NEONATAL MOUSE 
HEART SAMPLES 
 
Global non-targeted metabolomics of neonatal mouse hearts were 
performed with UHPLC-Orbitrap-MS (Table 1) and GCxGC-MS (Table 2) 
(publication I).66 GCxGC-MS raw data were processed with ChromaTOF. 
Guineu was used for compound alignment based on RI, retention times of both 
dimensions, and EI spectral matches.218 Data was further filtered and peaks 
were identified based on RIs and EI spectral match from in-house library, 
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NIST 2014 (http://chemdata.nist.gov/), GMB,240 or Fiehn library.241 LC-MS 
raw data was processed with MzMine 2 applying preprocessing steps, mass 
detection, chromatogram builder, chromatogram deconvolution, deisotoping, 
alignment, filtering, cap filling, and normalization with ISTD, and tissue 
weight. 206 Selected features were further identified with MS/MS analysis 
using mzCloud (https://www.mzcloud.org/), NIST 2014 
(http://chemdata.nist.gov/), HMDB,221 MoNA 
(http://mona.fiehnlab.ucdavis.edu), LipidBlast,235 CSI:Finger ID,234 and 
known group-specific fragmentation of lipid species for identification based 
on the MS/MS spectra. Metabolomics datasets were analyzed with R 3.1.2 
(https://www.R-project.org) using PCA, one-way ANOVA (LC-MS), or t-tests 
(GCxGC-MS). Separate datasets were combined and analyzed with linear-
mixed effect (LME) model,253 where the first variable was the postnatal age 
and the second was the dataset. FDR correction (Benjamini and Hochberg) 
was used in all statistical tests. Metabolite set enrichment analysis (MSEA) and 
fuzzy c-means clustering were performed on all significantly changed (q<0.01) 
identified metabolites in the LME model.254,255 
 
Table 1 Experimental parameters for GCxGC-MS (publication I). 
Parameter Details 
Instrument LECO Pegasus 4D  and Agilent 7890 gas chromatograph  
Retention gap Deactivated fused silica (1.7 m × 0.53 mm) 
Column 1 RTXi-5MS column (10 m × 0.18 mm, 0.2 μm) 
Column 2 BPX-50 column  (1.5 m × 0.1 mm, 0.1 μm ) 
Temperature program (1st oven) 50°C (2 min) → 240°C (7 °C/min) → 300°C (25 °C/min) → 300°C (3 min) 
Temperature program (2nd oven) 1st oven temperature + 20°C 
Modulation time 4 s 
Injection volume 1 μL 
Injection mode Pulsed splitless (1.5 min) 
Injector temperature  240°C  
Transfer line temperature  260°C  
Ion source temperature  200°C 
Carrier gas  Helium, 40 psig 
Ionization EI, 70 eV 
Mass range m/z 45-700 
Scan speed 100 spectra/s 
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Table 2 Experimental parameters for LC-MS (publication I). 
Parameter Details 
Instrument Thermo Orbitrap Fusion, Thermo Dionex Ultimate 3000 UHPLC  
Column  Acquity BEH C18 (2.1 x 100 mm, 1.7 μm) 
Eluents (set 1) A: 0.1% FA in MQ water, B: 0.1% FA in MeOH 
Eluents (set 2) A: 0.1% FA+ 5% MeOH in MQ water, B: 0.1% FA in MeOH 
Gradient of B (set 1) 5% → 100% (15 min) → 100% (10 min) → 5% (0.1 min) → 5% (4.9 min) 
Gradient of B (set 2) 0% → 100% (15 min) → 100% (10 min) → 5% (0.1 min) → 5% (4.9 min) 
Flow rate 0.3 mL min-1 
Injection volume 2 μL or 3 μL 
Column temperature 25°C 
Sample temperature 10°C 
Capillary voltage 3 kV 
Resolution 120 000 FWHM 
Sheet gas 30 arb 
Aux gas 10 arb 
Ion transfer tube 
temperature 333°C 
Vaporizer temperature 317°C 
Ionization  ESI, positive ion mode 
Mass range m/z 100-1000 
Scan speed 0.6 s 
MS/MS parameters HCD fragmentation, Normalized collision energies 25% and 40%, resolution 30 000 FWHM 
 
3.3.2 LIPIDOMICS ANALYSIS OF HUMAN SERUM SAMPLES 
 
Lipidomics of human serum samples were performed with UHPLC-QTOF-
MS (Table 3) (publication II).256,257 The data were processed using MZmine 2 
preprocessing steps, mass detection, chromatogram builder, chromatogram 
deconvolution, deisotoping, alignment, filtering, and cap filling.206 Serum 
lipids were identified using an internal spectral library or with additional 
MS/MS or MSn analysis. Data were normalized using the ISTD representatives 
of each lipid class. Serum polar metabolites were analyzed with GCxGC-MS.66 
Co-abundant serum metabolites (lipids and polar metabolites separately) were 
clustered with weighted correlation network analysis across all examined 
individuals after log2 transformation using the R package WGCNA.258 All 
statistical tests were non-parametric, applied FDR correction, and were 
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performed with R. Serum metabolite clusters and species associations with IR 
were conducted with a Spearman rank correlation test and all associations for 
microbial functional modules were identified using Mann-Whitney U-test. 
Ranks were based on Spearman correlation coefficients for associations of 
microbial functional modules with homeostatic model assessment for insulin 
resistance (HOMA-IR), gene richness, and serum metabolite clusters. More 
detailed description of data analysis can be found from original publication 
(II). 
 
Table 3 Experimental parameters for LC-MS (publication II). 
Parameter Details 
Instrument Waters QTOF Premier, Waters Acquity UPLC 
Column  Acquity BEH C18 (2.1 x 100 mm, 1.7 μm) 
Eluents A: 1% 1 M NH4Ac + 0.1% FA in MQ water, B: 1% 1 M NH4Ac + 0.1% FA in ACN/IPA (1:1) 
Gradient of B 35% → 80% (2 min) → 100% (5 min) → 100% (7 min) → 35% (0.1 min) → 35% (3.9 min) 
Flow rate 0.4 mL min-1 
Injection volume 1 μL 
Column temperature 50°C 
Sample temperature 10°C 
Capillary voltage 3 kV 
Resolution 8 000 FWHM 
Source temperature 150°C 
Desolvation temperature 450°C 
Desolvation gas flow 800 L h-1 
Cone gas flow 20 L h-1 
Mass range m/z 300-1200 
Scan speed 0.2 s 
MS/MS and MSn Waters Acquity UPLC-TriVersa Nanomate-Thermo LTQ Orbitrap 
 
3.3.3 LC-MS AND CHIP-MS METHODS IN GLOBAL  
METABOLOMICS ANALYSIS OF CELL SAMPLES 
 
Global non-targeted metabolomics of HFF and hiPSC samples were 
performed with SU-8-based ESI microchip Orbitrap MS and UHPLC-ESI-
QTOF-MS (Table 4) (publication III). The direct infusion ESI SU-8 chips were 
coupled to a Q-Exactive Hybrid Quadrupole Orbitrap Mass Spectrometer and 
controlled via Xcalibur software.259,260 A custom-made high-voltage supply 
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was used for application of the ESI voltage (2.5 kV) via a platinum electrode 
inserted into the sample inlet. The spectrum was recorded for 0.3 min and 
each sample was analyzed in triplicate. The microchip channel was carefully 
rinsed with MeOH:H2O (1:1) between runs.  
Both datasets (chip-MS and LC-MS) were processed with MZmine 2,206 
applying mass detection, chromatogram builder, chromatogram 
deconvolution (LC-MS only), deisotoping, alignment, filtering, and cap filling. 
Both datasets were normalized with ISTD verapamil. For chip-MS, the average 
abundance of three replicate measurements was calculated and further 
applied in the data analysis. Identification of detected compounds was based 
on search with accurate mass (3 ppm) from the HMDB and Lipid Maps 
databases.221,223 Data analyses of both datasets were performed with R 3.0.2. 
Zero-value imputation, log2 transformation, and centering were executed 
prior the PCA. Unpaired t-test with FDR correction was applied and fold 
changes were calculated for both datasets.   
 
Table 4 Experimental parameters for LC-MS and Chip-MS (publication III). 
Parameter LC-MS Chip-MS 
Instrument Waters Xevo QTOF,  Waters Acquity UPLC 
Thermo Q Exactive Hybrid 
Quadrupole Orbitrap  
Column  Acquity BEH C18 (2.1 x 100 mm, 1.7 μm) - 
Eluents A: 0.1% FA in MQ water, B: 0.1% FA in MeOH - 
Gradient of B 
5% → 100% (15 min) → 100% 
(10 min) → 5% (0.1 min) → 5% 
(4.9 min) 
- 
Column temperature 25°C - 
Flow rate 0.3 mL min-1 - 
Sample temperature 10°C - 
Injection volume 5 μL 5 μL 
Capillary voltage 2 kV 2.5 kV 
Resolution 8 000 FWHM 70 000 FWHM 
Source/Ion transfer tube 
temperature 150°C 200°C 
Desolvation temperature 450°C - 
Desolvation gas flow 800 L h-1 - 
Cone gas flow 20 L h-1 - 
Mass range m/z 100-1000 m/z 100-1500  
Scan speed 0.15 s 0.33 s 
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3.3.4 CAPILLARY PHOTOIONIZATION 
 
 
The CPI ion source (publication IV and V) contained a stainless steel (SS) 
CPI capillary (i. d. 1.5 mm) connected to a flat SS part with an oval-shaped 
opening (length 17 mm, width 8 mm at the widest point, height 3 mm) that 
was covered with a 3-mm thick magnesium fluoride (MgF2) window. A SS top 
plate with an 18-mm circular opening and graphite rings used as seals held the 
MgF2 window in place. The inlet where the analytes entered the ion source was 
heated by a resistance wire heater driven by a direct current power supply. The 
main body of the CPI device was heated (225-350°C) with a 100 or 160 W 
cylindrical heater (diameter 6.5 mm, length 50 mm) that was controlled by a 
PID500 temperature controller. The heater was embedded in a cylindrical 
aluminium block (diameter 35 mm, height 55 mm) that was attached to the 
bottom of the CPI device. The photoionization was performed with 10.0 and 
10.6 eV photons from a radio frequency krypton discharge vacuum UV lamp. 
3.3.4.1 GC-CPI-MS/MS for steroid analysis 
 
A gas chromatograph was connected through a capillary photoionization 
interface to the inlet of a mass spectrometer (Figure 5) to analyze steroids 
(Table 5) (publication IV). Inside the GC oven, the GC transfer capillary was 
introduced through a SS T-piece into a SS transfer tube, which was heated and 
served as a transfer line between the GC and MS. A few millimeters of this 
transfer tube and of the transfer capillary were introduced inside the CPI inlet 
capillary. A mixture of auxiliary gas nitrogen and dopant chlorobenzene 
entered the t-piece through 1/16 in o.d. SS tubing. The dopant was pumped 
into the t-piece by a syringe pump and vaporized and mixed with auxiliary gas 
before the t-piece. Inside the SS t-piece, the mixture was directed into the SS 
transfer tubing and was transferred coaxially with the transfer capillary into 
the CPI capillary. A nitrogen atmosphere was created around the CPI inlet 
capillary and the GC transfer tube interface by enclosing them in aluminium 
housing, which was sealed and insulated with aluminium foil wrapped around 
the housing. The housing was not completely gas tight to allow the vacuum 
system of the MS to produce equal gas flow as without the nitrogen housing. 
However, the excess nitrogen prevented most of the ambient air molecules 
from entering the ion source.  
EXPERIMENTAL 
46 
 
Figure 5 Setup for GC-CPI-MS. Parts marked in the figure are 1.GC oven, 2. GC transfer 
capillary, 3.  SS t-piece, 4. SS transfer tube (i. d. 0.5 mm), 5. Heated transfer line, 6. Heated CPI 
inlet capillary, 7. Dopant and nitrogen gas line (1/16 in o.d. SS tubing), 8. Nitrogen atmosphere in 
an aluminium housing, 9. Nitrogen flow through Teflon tubing, 10. Oval-shaped opening under 
MgF2 window, 11. Heated aluminium block, 12. Temperature control of cylindrical heater 13. CPI 
capillary, 14. Inlet into mass spectrometer. Parts 5. and 8. were insulated with aluminium foil 
(publication IV).  
Table 5 Experimental parameters for GC-MS/MS (publication IV). 
Parameter Details 
Instrument Agilent 6410 triple quadrupole, HP 5892 II gas chromatograph 
Retention gap column Deactivated fused silica (2 m, i.d. 0.25 mm) 
Column 1 TR-5MS (15 m, i.d. 0.25 mm, film thickness 0.25 μm) 
Column 2 TR-50MS (15 m, i.d. 0.25 mm, film thickness 0.25 μm) 
Transfer line 1 m, i.d. 0.15 mm  deactivated fused silica 
Temperature program 190°C (1 min) → 250°C (10°C min
-1) → 260°C (1°C min-1) 
→ 330°C (7°C min-1)→ 330°C (3 min) 
Injection volume 3 μL min-1 
Injection mode Splitless (1 min) 
Injector temperature  250°C 
Transfer line temperature  250°C 
Carrier gas  Helium, 140 kPa 
CPI source temperature  250°C 
Auxiliary nitrogen gas 80 mL min-1 
Dopant flow rate 3 μL min-1 
Nitrogen housing flow rate  4.5 L min-1 
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3.3.4.2 GC-CPI-MS/MS method validation and analysis of steroids 
from urine  
 
The GC-CPI-MS/MS method was developed, validated, and applied for human 
urine samples to analyze 18 endogenous steroids (publication IV). Steroids 
were quantified with an ISTD method and identification was based on 
retention time and ion ratios of the selected product ions. The developed 
method was validated following the validation instructions of The 
International Council for Harmonisation (ICH) and identification criteria of 
World Anti-Doping Agency (WADA).261,262 Limit of detection (LOD), limit of 
quantitation (LOQ), linear range, linearity, repeatability, LLE recovery, and 
carryover were studied. In total, 21 different concentration levels in the range 
0.001-5000 ng mL-1 spiked to artificial urine were tested for determination of 
linearity, linear range, LOD, and LOQ. LOD and LOQ were determined based 
on the signal-to-noise (S/N) ratio using criteria S/N >3 and S/N >10 with 
spiked standard compounds in artificial urine, respectively. A suitable linear 
range and LOQ fulfilled the following criteria: maximum residual from the 
curve below 20% or below 30% (LOQ) and quantifier/qualifier ion ratio in the 
range instructed by WADA.262 For ADT, ETIOL, and CS, an additional curve 
from diluted samples was determined and applied to analyze high urine 
concentrations.  1/x weighting was applied for the calibration curves. 
Repeatability and LLE recovery were determined at a concentration level of 10 
ng mL-1 (n=6).  
3.3.4.3 LC-CPI-MS 
 
The LCs used in the study (publication V) were Waters Acquity UPLC and 
Agilent 1100 capillary LC system The column was Waters BEH C18 (2.1 mm x 
100 mm, 1.8 μm) in UHPLC-MS experiments. The eluents were (A) MQ water 
and (B) MeOH with the following gradient: B 10-100%, 0-5 min; B 100%, 5-10 
min; B 100-10%, 10-10.1 min; and B 10%, 10.1-15 min. The flow rate was 200 
μL min-1 and the flow was split after the column with a split ratio of 1:20. The 
injection volume was 10 μL. The column was Waters Symmetry RP18 (0.3 mm 
x 100 mm, 3.5 μm) in capillary LC-MS experiments. The eluents were (A) MQ 
water and (B) MeOH with the following gradient: B 10-100%, 0-10 min; B 
100%, 10-15 min; B 100-10%, 15-20 min; and B 10%, 20-60 min. The flow rate 
was 10 μL min-1 and the injection volume was 1 μL.  
The eluent from the LC column was directed to the CPI device through 
fused-silica transfer capillary (0.15 mm i.d.) passing through an SS t-piece and 
SS tubing (Figure 6). The end of the transfer capillary was positioned inside 
the CPI capillary in front of the MgF2 window. Toluene as a dopant was 
pumped at a flow rate of 5 μL min-1 and mixed through a t-piece with nitrogen 
used as an auxiliary gas (400 mL min-1). The nitrogen-dopant gas mixture was 
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heated with a resistant wire heater (approximately 110-120°C) that led into the 
SS t-piece and passed coaxially between the fused silica transfer capillary and 
the SS tubing inside the CPI device. An Agilent 6410 triple-quadrupole mass 
spectrometer was used in all experiments applying Mass Hunter for data 
acquisition and for data processing. DHEA, PROG, E2, and T were used as test 
compounds. The following optimized (fragmentor voltage and collision 
energy) mass transitions were used: DHEA, m/z 271 ([M+H-H2O]+) → 213; 
E2, m/z 255 ([M+H-H2O]+) → 159; PROG, m/z 315 ([M+H]+) → 97; and T, 
m/z 289 ([M+H]+) → 97. 
 
Figure 6 Setup for LC-CPI-MS. Published by The Royal Society of Chemistry (publication V). 
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4 RESULTS AND DISCUSSION 
This chapter summarizes the main results of the work. More detailed 
descriptions can be found in the original publications (I-V). The overall aim 
was to apply mass spectrometric methods and to develop new faster and more 
sensitive methods for metabolomics. Since none of the existing analytical 
methodologies can detect all metabolites simultaneously, multiple methods 
with different advantages and disadvantages are required for wide metabolite 
coverage. Neonatal mouse heart samples (publication I) and human serum 
samples (publication II) were studied with non-targeted methods applying LC-
MS and GCxGC-MS. The aim in both studies was to detect metabolic changes 
as widely as possible without a previous hypothesis of possible changes. 
However, sample throughput is limited when chromatographic separation is 
used and long batches may be prone to retention time shifts or drift in signal 
sensitivity. To overcome this, the feasibility of a direct infusion ESI microchip 
MS for global non-targeted metabolomics to detect differences between hiPSC 
and HFF cells was studied (publication III). The developed method was 
compared to more traditional LC-MS and the performance of both methods in 
metabolomics was evaluated.  
When quantitative analysis of high sensitivity and specificity is required, 
non-targeted methods are usually not adequate and targeted methods are 
required. The ESI ionization technique is applied in nearly all metabolic 
applications with LC, although ionization efficacy of ESI towards highly non-
polar compounds is weak and insufficient to detect non-polar metabolites at 
low concentrations. On the other hand, in GC applications the ion source is 
usually EI, where sensitivity is not maximal because of intense fragmentation. 
To increase sensitivity, a CPI ion source was developed and applied in GC-MS 
and LC-MS, which enabled high ion transmission efficacy with low 
fragmentation. A GC-CPI-MS/MS method was developed and validated to 
detect steroids in human urine to study the feasibility of the interface in 
metabolic applications (publication IV). The suitability of the CPI interface for 
LC-MS applications was explored for the first time, using low flow rates (10 μL 
min-1) that are not optimal with the existing commercial APPI ion source 
geometries that require higher flow rates (>200 μL min-1) (publication V). 
4.1 GLOBAL METABOLOMICS OF NEONATAL MOUSE 
HEARTS 
The aim of this study was to develop a method for global metabolomics and 
detection of metabolic changes to identify the molecular mechanisms 
mediating postnatal loss of cardiac regeneration in mammals (publication I). 
Previous studies have shown that neonatal rodents can fully regenerate their 
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hearts after an injury. However, this regenerative capacity is lost within 7 days 
after birth because of cardiomyocyte cell cycle withdrawal.263 The reported full 
functional recovery of a newborn baby with a massive myocardial infarction 
suggests that humans possess a similar intrinsic capacity for heart 
regeneration after birth.264 Understanding the biology behind the loss of 
regeneration capacity plays a key role in the development of regeneration-
inducing therapies, which are essential for diseases with massive cell losses 
(i.e. stroke and myocardial infarction). An integrated multiomics study of 
mRNA, protein, and metabolite changes was performed from neonatal mouse 
hearts to identify metabolism-related mechanisms associated with cardiac 
regeneration. For this study, two individual sample sets of mouse hearts at 
postnatal days 1, 4, 9, and 23 (P01, P04, P09, P23, respectively) were analyzed 
(Figure 7). 
 
 
Figure 7 The experimental design of study (publication I). 
4.1.1 GLOBAL METABOLOMICS USING LC-MS 
 
Complementary techniques (LC-MS and GCxGC-MS) were used for non-
targeted metabolomics to increase the metabolite coverage. Two individual 
sample sets (set 1 and set 2) were used to increase reliability and decrease the 
possibility of false findings and artifacts. First, simple PPT with MeOH 
combined with ESI-RPLC-MS analysis in positive ion mode was selected for 
global metabolic profiling. In total, 5591 (set 1) and 9043 (set 2) features were 
detected with LC-MS with 3398 matching features from both sample sets. 
Metabolic differences were studied with PCA, t-tests, ANOVA, and LMEA 
model from combined dataset (set 1 and 2).  The PCA of all features showed 
clear separation of the sample groups based on neonatal age (Figure 8A). 
Statistically significantly changed (q <0.01) metabolic features between the 
time points (P1 vs. P4, P1 vs. P9, and P1 vs. P23) in the LME model (n=805) 
were forwarded to identification with additional MS/MS analysis. Metabolites 
were mainly detected as protonated molecules, although sodium adducts were 
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also detectable for most of the species. The LC-MS method was able to detect 
significantly changed polar compounds, including amino acids and purines, 
lipids such as free fatty acids, lysophospholipids (LPL), monoacylglycerols 
(MG), acylcarnitines, phosphatidylcholines (PC), phosphatidylethanolamines 
(PE), ceramides (Cer), and sphingomyelins (SM). Unfortunately, most of the 
detected features remained unknown. Highly non-polar lipids were not 
detected (i.e. triacylglycerols [TG] or cholesterylesters [ChoE]) due to selection 
of PPT solvent and LC eluents and the detected polar compounds were mainly 
eluted in the void volume. Some phospholipid (PL) classes, such as 
phosphatidic acids (PA), phosphatidylglycerols (PG), phosphatidylinositols 
(PI), and phosphatidylserines (PS) and some polar compounds (e.g. organic 
acids) were not detected and would have required ionization in the negative 
ion mode. The quality of the method was controlled with pooled QC samples 
(Figure 8A) and monitoring intensities of ISTDs (Table 6). Repeatability and 
mass accuracy were adequate and no signal drift was observed when the 
sample injection order was inspected. 
 
 
Figure 8 Individual factor maps of PCA of LC-MS (A) and GCxGC-MS (B) data of sample set 2 
(publication I). P01, P04, P09, and P23, postnatal days 1, 4, 9, and 23; QC, quality control. 
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Table 6 Exact masses, accurate masses, RTs, mass errors, and relative standard deviations (RSD 
%) of the ISTDs in heart sample sets 1 (n=44) and 2 (n=39), including pooled QC samples in 
sample sets 1 (n=10) and 2 (n=10) measured with LC-MS using Orbitrap mass spectrometer 
(publication I). 
Compound Exact mass  Accurate mass RT (min) 
Mass error 
(ppm) 
RSD% 
intensity 
RSD% normalized 
intensity 
Sample set 1             
LysoPC(17:0) 510.35542 510.35524 15.84 0.35 24.8 0 
Propranolol 260.16451 260.16434 9.48 0.67 25 17.7 
L-Lysine-d4 151.13790 151.13794 0.78 -0.25 23.4 21.2 
Verapamil 455.29043 455.29018 10.15 0.56 16.3 15.4 
Sample set 2       
LysoPC(17:0) 510.35542 510.35522 16.01 0.38 11.7 0 
Propranolol 260.16451 260.16431 9.24 0.78 12.9 14.5 
L-Lysine-d4 151.13790 151.13793 0.78 -0.23 22.8 24.2 
Verapamil 455.29043 455.29019 9.9 0.52 12.9 14.5 
 
4.1.2 GLOBAL METABOLOMICS USING GCXGC-MS 
 
Since the polar metabolites were detected with LC-MS mainly in the void 
volume without a proper separation, an additional GCxGC-MS experiment 
was designed. GCxGC-MS analysis was performed after PPT with MeOH and 
automated two-step derivatization. After the first data preprocessing steps, the 
GCxGC-MS datasets of sample set 1 and 2 contained 760 and 771 metabolic 
features, respectively. Peak lists were further filtered resulting in a total of 347 
and 443 features. Of these, 328 features were found from both datasets and 
contained in total 162 statistically significantly (q <0.01) changed metabolic 
features in the LME model. A wide range of polar metabolites, including 
sugars, organic acids, amino acids, TCA cycle metabolites, and vitamins were 
detected and identified based on RI and EI spectral match either from an in-
house library or spectral databases. However, most of the detected features in 
this data remained also unknown. The quality of the GCxGC-MS method was 
monitored with internal and injection standards and pooled QC samples 
(Figure 8B, Table 7). Repeatability based on ISTDs were acceptable (Table 7). 
In addition to semi-quantitative non-targeted analysis, some of the 
metabolites were targeted and quantified against a standard calibration curve 
(Table 7). 
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Table 7 Relative standard deviations (RSD%) of the ISTDs and injection standard (inj. st.) 
intensities in heart sample sets 1 (n=44) and 2 (n=39) and quantified compounds in pooled QC 
heart sample sets 1 (n=10) and 2 (n=10) measured with GCxGC-MS (publication I). 
Compounds RSD% 
Internal and injection standards Sample set 1 Sample set 2 
succinic acid-d4 (ISTD), 2 TMS 11 21 
heptadecanoic acid-d33 (ISTD), TMS 9 8 
4,4ʹ-dibromooctafluorobiphenyl (inj. st.) 14 14 
Quantified compounds    
3-Hydroxybutyric acid, 2TMS 16 14 
Alanine, 2TMS 12 18 
Arachidonic acid, TMS 50 28 
Aspartic acid, 3TMS 62 78 
Cholesterol, TMS 12 17 
Citric acid, 4TMS 11 26 
Fumaric acid, 2TMS 5 21 
Glutamic acid, 3TMS 4 5 
Glycine, 3TMS 19 37 
Isoleucine, 2TMS 23 24 
Leucine, 2TMS 31 20 
Linoleic acid, TMS 20 13 
Malic acid, 3TMS 7 7 
Oleic acid, TMS 17 9 
Palmitic acid, TMS 19 14 
Proline, 2TMS 45 23 
Serine, 3TMS 35 30 
Stearic acid, TMS 26 19 
Succinic acid, 2TMS 14 16 
Threonine, 3TMS 24 22 
Valine, 2TMS 3 7 
4.1.3 CHANGED METABOLITES AND METABOLIC PATHWAYS 
IN NEONATAL MOUSE HEARTS 
 
Applying the LME model, a total of 151 metabolites were identified with a 
statistically significant (q <0.01) change related to postnatal age with either 
LC-MS, GCxGC-MS, or both. Changed features are presented in a heatmap 
(Figure 9) showing statistical significance, clustering of metabolites, and 
upregulation or downregulation of metabolites compared to postnatal day 1. 
The metabolomics data showed a distinct shift from carbohydrates to lipids as 
the main source of energy and an increase in total energy metabolism over the 
early postnatal period (Figure 9). The same shift was also detected in 
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transcriptomics and proteomics. The abundances of glucose and sugar 
derivatives (glucose, glucose-6-phosphate, fructose-6-phosphate, galactose-6-
phosphate) were downregulated at P23 compared with P01 (Figure 9B), 
whereas the abundances of most fatty acids and components of glycerolipid 
metabolism (glycerol-3-phosphate, glycerol-2-phosphate, glycerol, glyceric 
acid) increased after P01 (Figure 9). The abundance of acylcarnitines at P04 
and P09 also increased, reflecting increased fatty acid β-oxidation (Figure 9A). 
Most metabolites of the TCA cycle (citric acid, fumaric acid, pyruvic acid, malic 
acid, lactic acid), pentose-phosphate pathway (D-seduloheptulose-7-
phosphate), and glycolysis (lactic acid, pyruvic acid) revealed a constant rise 
with increasing postnatal age (Figure 9B), thus indicating an increase in 
energy metabolism in general. Various lipid species (PLs, LPLs, MGs, and fatty 
acids) also showed interesting changes in abundance (Figure 9A). For PLs, 
there was a general trend toward increasing saturation level along with 
increasing postnatal age. All PLs that exhibited a constant decrease from P01 
to P23 were unsaturated, and many were polyunsaturated. The PL species with 
saturated medium-to-long-chain fatty acids (e.g. PC(24:0), PC(26:0), 
PC(28:0)) exhibited an increase at P04 and P09 followed by a decrease at P23. 
Several LPL species (LysoPC and LysoPE) increased at P04 and remained 
constant or increased further through P09 to P23, with the exception of LPLs 
with fatty acids 16:1 and 18:1, which decreased after P01, or 14:0, which 
decreased after P04. Interestingly, myristic acid (C14:0) revealed a 
comparable pattern both as a free fatty acid and when incorporated into other 
lipid species (e.g. Cer, SM, or PC). The abundance of C14:0-containing species 
increased at P04 and P09 and decreased at P23. A similar pattern was also 
observed for other medium-chain saturated fatty acid species (e.g. C12:0 and 
C10:0) (Figure 9A). The levels of most amino acids displayed an initial increase 
at P04 or P09 (or both) followed by a decrease at P23 (Figure 9B). In contrast 
to other (proteinogenic) amino acids, the abundance of glutamic acid, alanine, 
and histidine increased initially but remained significantly higher at P23 
compared to P01 (Figure 9B). The increase in amino acid abundance from P01 
to P09 likely reflects the active protein synthesis vital for cardiomyocyte 
growth and maturation. This was also observed in the MSEA, where the most 
changed metabolic pathway was protein biosynthesis followed by the urea 
cycle, glycerolipid metabolism, alanine metabolism, and enrichment of 
multiple individual amino acid metabolic pathways. Significant changes were 
also observed in purine metabolism, particularly among the metabolites of 
AMP catabolism. The level of AMP had decreased already at P04, paralleled 
by an increase in the abundance of its degradation pathway metabolites, such 
as inosine, hypoxanthine, and xanthine (Figure 9B). Consistent with the 
postnatal increase in cardiac workload, we also observed an increased 
abundance of creatine and creatinine at P09 and P23 compared with P01. 
Furthermore, an increase in ascorbic acid metabolites L-threonic acid and 
threonic acid 1,4-lactone on P09 and P23 was observed, reflecting increased 
oxidative stress with increasing postnatal age. 
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Figure 9 Metabolite changes in the postnatal mouse heart. A, Heatmap of linear mixed effect (LME) 
model estimates for lipids (A) and polar metabolites (B) compared to postnatal day 1 (P01). *q<0.01 
compared with P01. Cer indicates ceramide; FA, fatty acid; LysoPC, lysophosphatidylcholine; 
LysoPE, lysophosphatidylethanolamine; MG, monoacylglycerol; PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; SM, sphingomyelin (publication I). 
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4.1.4 MULTIOMICS OF NEONATAL MOUSEHEARTS 
 
Transcriptomics, proteomics, and metabolomics were also studied in 
parallel to gain insight into the mechanism of postnatal cardiac maturation. 
For this, information from fuzzy c-means clustering, enriched biological 
process gene ontology (GO) terms, RNAseq and proteomics KEGG pathways, 
ingenuity pathway analysis (to identify potential upstream regulators of gene 
and protein expression changes), and metabolic pathways enriched in MSEA 
were utilized.  The most significant changes observed at all omics levels were 
branched-chain amino acid (BCAA) catabolism, fatty acid metabolism, 
mevalonate and ketogenesis pathways (Figure 10), thus revealing possible 
associations with regeneration capacity or regulation of the cardiomyocyte cell 
cycle.  
Since hydroxymethylglutaryl-CoA synthase 2 (HMGCS2) was the most 
significantly upregulated protein from P01 to P04 and cholesterol biosynthesis 
was one of the enriched metabolism-related biological processes in GO 
enrichment analysis, the mevalonate pathway and ketogenesis were studied 
further. Changes were also detected at the metabolite levels of these pathways, 
including levels of 3-hydroxybutyric acid, the end product of ketogenesis and 
cholesterol levels, the metabolite of the mevalonate pathway end product. To 
evaluate the role of the mevalonate pathway and ketogenesis in cardiomyocyte 
proliferation, the effects of pharmacological HMGCS and 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGCR) inhibition on the viability and 
proliferation of neonatal rat ventricular cardiomyocytes was investigated. 
Simultaneous inhibition of the mevalonate and ketogenesis routes with 
hymeglusin decreased the percentage of proliferating cardiomyocytes (BrdU 
levels) with nontoxic concentrations (Figure 10). However, inhibition of the 
mevalonate pathway alone using the HMGCR inhibitor simvastatin showed no 
effect on the percentage of proliferating cardiomyocytes at nontoxic 
concentrations (Figure 10). These results indicate that the HMGCS-mediated 
ketogenesis may participate in regulating cardiomyocyte cell cycle activity. 
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Figure 10 Ketogenesis and mevalonate pathways in the postnatal heart (A). B, Relative mRNA 
expression of selected ketogenesis and mevalonate pathway components (mean±SEM; n=3 
pooled samples, each from 3 hearts). C, Normalized label-free quantification intensities of proteins 
detected in the ketogenesis and mevalonate pathways. D, Concentrations of 3-hydroxybutyrate 
and cholesterol over the early postnatal period. E and F, Effect of HMGCS inhibition with 
hymeglusin and HMGCR inhibition with simvastatin on neonatal rat ventricular cardiomyocyte 
viability using the MTT assay (E) and proliferation quantified as the percentage of 
bromodeoxyuridine (BrdU)-positive cells after 24-hour exposure (F). Data are expressed as 
mean±SEM from 3 independent experiments. *P<0.05, **P<0.01 compared with control (Ctrl); 
Welch ANOVA followed by Games-Howell. BDH1, 3-hydroxybutyrate dehydrogenase 1; FBS, fetal 
bovine serum; HMGCL, hydroxymethylglutaryl-coenzyme A lyase; IDI1, isopentenyl-diphosphate 
d-isomerase 1; MVD, mevalonate diphosphate decarboxylase; MS1, precursor ion mass spectrum; 
MVK, mevalonate kinase; OXCT1, 3-oxoacid CoA-transferase 1; PMVK, phosphomevalonate 
kinase (publication I). 
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4.2 METABOLOMICS OF HUMAN SERUM RELATING 
GUT MICROBIOTA AND INSULIN SENSITIVITY 
In this study, we assessed the role of the gut microbiome as a source for key 
features of the serum metabolome profile that predicts metabolic and 
cardiovascular disorders in non-diabetic individuals (publication II). The 
metabolic phenotype corresponding to an insulin-resistant (IR metabotype) 
or insulin-sensitive (IS metabotype) phenotype was determined based on 
HOMA-IR and metabolic syndrome defined according to the International 
Diabetes Federation. The serum metabolic profile was determined by 
analyzing polar metabolites with GCxGC-MS and lipidomics with LC-MS. 
Serum metabolites were associated with the IR and IS metabotypes and results 
were further validated with type 2 diabetes patients. To evaluate the role of gut 
microbiota in insulin resistance (IR), gut microbiome metagenomics was 
analyzed and microbiome functional modules were further associated with IR 
and IS metabotypes and serum metabolite clusters. 
4.2.1 LIPIDOMICS ANALYSIS OF SERUM SAMPLES 
 
Serum lipidomics was performed with UHPLC-QTOF in positive ion mode 
after modified Folch extraction.89,256,257 A total of 876 molecular serum lipid 
features were measured, including 289 identified and 587 unidentified 
features. The detected and identified lipid species were mainly LPLs, PLs such 
as PCs and PEs, Cer, SM, diacylglycerols (DG), TGs, and ChoEs. Some polar 
lipid classes (i.e. PI, PS, PA, PG) were not detected due to poor ionization 
efficacy in positive ion mode and weak extraction efficacy. Phosphatidic acids 
and lysophosphatidic acids are inadequately extracted in apolar solvents 
without pH adjustment with acidification,265 which would again increase the 
risk for phospholipid hydrolysis to lysophospholipids.266 The addition of 
ammonium buffer to eluent, however, enabled the formation of adducts and 
detection through adduct formation. The most abundant peaks of LPLs, PLs, 
Cer, and SM species were protonated ions, whereas non-polar lipids (DG, TG, 
and ChoE) were detected mainly as ammonium adducts.  
Adequate separation of lipid species with an RP column was obtained 
within a total run time of 18 min (Figure 11), although overlap of some isobaric 
TGs were observed.  Data quality was monitored with ISTD levels spiked to 
each sample and with additional quality control samples, blanks, control 
serum samples, and extracted and non-extracted standards. The RSD% of the 
ISTDs spiked into the samples were between 8-13% and the RSD% of the 
identified lipids in the control serum samples were on average 12.8%. 
Altogether, these values showed good analytical performance and neither 
sample preparation nor analysis order had any significant influence on the 
results.  
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Figure 11 Total ion chromatogram of RP-UHPLC-TOF-MS lipidomics from a serum sample 
showing separation of major lipid classes. LPL; Lysophosholipids, MG; Monoglycerides, PL; 
Phospholipids, SM; Sphingomyelins, Cer; Ceramides, DG; Diacylglycerols, TG, Triacylglycerols, 
ChoE; Cholesterylesters. 
4.2.2 METABOLITES CORRELATING WITH INSULIN 
RESISTANCE 
 
All detected metabolic features were included in the data analyses, including 
unidentified features. Serum lipids (in total 876, 289 known, 587 unknown) 
and polar metabolite features detected with GCxGC-MS (in total 325 polar 
metabolites, 94 known, 231 unknown) were combined and clustered with 
weighted correlation network analysis to 74 co-abundance clusters across all 
individuals, containing in total 39 lipid clusters.66 From these clusters, 19 were 
significantly and consistently associated with IR and metabolic syndrome 
from non-diabetic individuals and most of the associations were also 
confirmed in type 2 diabetes patients. These 19 clusters consisted of a total of 
26 polar metabolites from 5 separate clusters and 367 lipids from 14 clusters 
(Table 8). All clusters were further separated into two groups either correlating 
positively (IR metabotype) or negatively (IS metabotype) with both IR and 
metabolic syndrome. The serum metabolites and lipids associated with the IR 
phenotype were mainly amino acids including BCAA, TCA cycle metabolites, 
and TGs. Elevated serum BCAA levels, changed TCA cycle metabolites, TGs, 
and specific membrane phospholipids have also previously been associated  
with IR and future risk of metabolic and cardiovascular events.267–271 The IS 
metabotype contained only serum lipids (mainly PLs and TGs with odd carbon 
chains and high double bond content) and LysoPCs, LysoPEs, and SMs (Table 
8). These results also confirm previous findings that odd-chain fatty acids and 
polyunsaturated fatty acids are associated with reduced risk of type 2 
diabetes.269,272   
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4.2.3 CORRELATING HOST INSULIN SENSITIVITY AND 
METABOLIC SYNDROME, GUT MICROBIOME, AND 
FASTING SERUM METABOLOME  
 
The origin of serum metabolites associated with IR is unknown. In this study, 
we assessed the role of the gut microbiome as a source of IR-associated serum 
metabolites. For this, gut microbiome metagenomics of individuals from the 
study were analyzed and microbiome functional modules were further 
associated with IR and IS metabotypes. A total of 41 microbiome functional 
modules were significantly associated with one or more of the IR and 
metabolic syndrome phenotypes and furthermore associated with the IR and 
IS metabotypes (Table 8). The functional modules of the microbiome that were 
positively associated with both HOMA-IR and the IR metabotype contained 
enzymes for biosynthesis of BCAAs, cofactors, vitamins, lipopolysaccharides, 
and various transport systems (Figure 12). In contrast, the microbiome 
negatively associated with HOMA-IR and the IR metabotype contained 
functional modules important for methanogenesis, pyruvate oxidation, and 
transport systems, including inward transport of BCAAs (Figure 12). The 
microbial functional module analysis highlighted an increased BCAA 
biosynthesis potential, but depletion of genes encoding the transport system 
for bacterial inward BCAA transport in the gut microbiome of IR individuals. 
Microbial species contributing to the associations between the microbiome 
functional modules and HOMA-IR were identified with iterated correlation 
analysis. The positive associations between HOMA-IR and the biosynthesis 
modules of BCAA, tryptophan, and lipopolysaccharides were largely driven by 
Prevotella copri (P. copri) followed by Bacteroides vulgatus. P. copri also had 
a positive correlation with the BCAA-containing metabolite cluster M10 in the 
94 individuals with detectable levels of the species. Whereas the functional 
modules enriched in the gut microbiome of IR individuals were driven by 
relatively few microbial species each with high impact, all microbial functional 
modules associated with increased insulin sensitivity were driven by multiple 
species including Butyrivibrio crossotus and Eubacterium siraeum, all with 
minor effect. Accordingly, gene enrichment of the microbiome and presence 
of multiple species had a positive correlation with insulin sensitivity. These 
findings also suggest that elevated serum BCAA concentrations, which are 
known to associate with IR, are a joint effect of increased potential for BCAA 
biosynthesis and decreased inward BCAA transport of the gut microbiome. 
Since P. copri was the strongest driver species for the positive association 
between microbial BCAA biosynthesis in the gut and IR, the role of P. copri 
was studied experimentally. P. copri (n = 12) and sham-gavaged (n = 12) male 
mice (C57BL/6J) on a high-fat diet were studied. In 2 weeks, P. copri mice 
aggravated glucose intolerance and showed increased total serum BCAA 
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levels. Reduced insulin sensitivity of P.copri mice was observed after 3 weeks 
of P. copri challenge. 
 
 
 
Figure 12 Association map of the three-tiered analyses integrating the phenome, the gut 
microbiome, and the fasting serum metabolome in 277 non-diabetic individuals with available 
metagenomic data. The left panel shows significant associations (Mann-Whitney U-test FDR <0.1) 
between microbial functional modules and the indicated phenotypes; coloring indicates direction of 
association. The right panel shows associations between the same modules and serum metabolite 
clusters. Coloring represents the median Spearman correlation coefficient between metabolite 
clusters and the indicated functional modules. +, FDR < 0.1; *, FDR <0.01; **, FDR <0.001 
(publication II). 
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4.3 COMPARISON OF LC-MS AND CHIP-MS DIRECT 
INFUSION METHOD IN GLOBAL NON-TARGETED 
METABOLOMICS 
Rapid analysis from low sample volumes would be beneficial in large 
metabolic studies of clinical samples. Microchip-MS is considered as a 
potential technique for improving the sensitivity and cost-efficiency of 
metabolomics research, since it allows a rapid, straightforward analysis from 
low sample volume, and possibility for completely automated system in the 
future. In this work, we wanted to study the applicability of microchip-MS for 
non-targeted metabolomics (publication III). The feasibility of direct infusion 
electrospray ionization microchip mass spectrometry (chip-MS) was 
compared to the commonly applied liquid chromatography-mass 
spectrometry (LC-MS) in non-targeted metabolomics analysis of HFF and 
hiPSC cells reprogrammed from HFF.  
4.3.1 COMPARISON OF ANALYTICAL PERFORMANCE OF LC-
MS AND CHIP-MS 
 
Using the custom-fabricated SU-8-based ESI microchip Orbitrap MS 
method,259,260 the duration of the global metabolomics measurement was only 
0.3 minutes, which was adequate to measure high-quality spectra (Figure 13). 
The run time was 30 minutes with application of RP-UHPLC-ESI-QTOF-MS 
(Figure 13). Since high sample throughput is very important in large 
metabolomics studies (especially in clinical experiments), the short analysis 
time in chip-MS is a remarkable benefit compared to LC-MS.  
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Figure 13 Base peak chromatograms of HFF and hiPSC samples (A and C) with RP-UHPLC-ESI-
QTOF-MS with mass range 100-1000 m/z. Combined spectra of HFF and hiPSC samples (0.3 min) 
with SU-8-based ESI microchip Orbitrap MS (B and D) (publication III). 
A wide range of metabolites from polar small molecules to lipids were 
detected with both the chip-MS and the LC-MS methods (Fig 13). The main 
metabolites identified based on accurate mass were amino acids, amino acid 
derivatives, acylcarnitines, nucleotides, sugars, sugar phosphates, fatty acids, 
fatty acid and steroid derivatives, and a high number of lipids from classes 
such as MGs, PCs, PEs, and SM. In addition, several unidentified metabolites 
that include oxygen as a heteroatom in aliphatic structures (such as alcohols, 
esters, and carboxylic acids) were found based on the accurate mass 
measurements. The metabolites were detected as their protonated molecules 
or sodium or potassium adduct ions (or a combination of these). Adduct ions 
were observed as the cell samples contained residual sodium and potassium 
salts after the extraction. In LC-MS, adduct formation was less abundant due 
to separation and elution of salts in the void volume and mainly protonated 
molecules were formed. In chip-MS, significantly more abundant adduct ions 
were detected, as the residual salts were not chromatographically separated 
from metabolites and the higher salt concentration in the ESI favored adduct 
ion formation. Analyte presence as multiple abundant ions may decrease 
sensitivity. However, salts may also be beneficial and assist ionization of some 
low proton affinity metabolites, which are poorly ionized via a proton transfer 
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reaction but are ionized more efficiently via adduct ion formation.273 Some 
metabolites (including low proton affinity compounds in compound classes, 
carboxylic acids, amino acids, carnitines, sugar derivatives, sugar phosphates, 
phosphates, and nucleosides) were detected only with chip-MS as their adduct 
ions but were not detected in the LC-MS.   
The total number of the detected features with chip-MS and LC-MS were 
619 and 1959, respectively. The difference in the number of detected features 
is largely explained with peak capacity and the sensitivity of the applied 
analytical method. The lower peak capacity with the chip-MS results in an 
increased number of overlapping features, particularly with lipids (Figure 14). 
In the LC-MS data of hiPSC and HFF, the extracted ion chromatograms of m/z 
806.57 (∆m/z 0.04) showed several peaks, whereas the chip-MS spectrum 
showed only one peak between m/z 806.5-806.6; differences of individual 
lipid species between hiPSC and HFF were not observed (Figure 14). 
Investigation of the spectra detected in the extracted ion LC-MS 
chromatogram of m/z 806.57 at retention times of 17.53 and 17.33 min 
revealed that these most likely represent isomers of [PC(38:6)+H]+ (exact 
mass m/z 806.5694), and the peaks at 17.88, 18.0, and 18.19 min represent 
isomers of [PC(36:3)+Na]+ (exact mass m/z 806.5670) (Figure 14). The mass 
difference between the ions [PC(38:6)+H]+ and [PC(36:3)+Na]+ is only 2.4 
mDa, which means that mass resolution over approximately 350 000 would 
have been required to distinguish these ions in the chip-MS spectra. In 
addition, the [M+2] isotopes of lipids may overlap with lipids belonging to the 
same lipid class but with one less double bond (Figure 14). Overlap of 
metabolic features may especially hinder the detection of differences of less 
abundant metabolites between samples and the use of LC-MS provides 
significantly better selectivity and thus more detailed information in non-
targeted metabolomics than direct MS.  
Another reason for the lower number of detected features with chip-MS is 
ion suppression, which is more evident in chip-MS than in LC-MS. Salts and 
some easily ionized phospholipids in ESI (such as phosphatidylcholines) may 
suppress ionization of metabolites that have lower ionization efficiency.274,275 
For example, the intensities of several LPLs were below the detection 
threshold in chip-MS but were clearly detected with LC-MS.  
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Figure 14 RP-UHPLC-ESI-QTOF-MS ion chromatograms of detected features at m/z 806.57 (∆m/z 
0.04) from HFF and hiPSC samples (A and C). The peaks in the chromatograms correspond to 
protonated phosphatidylcholine [PC(38:6)+H]+, phosphatidylcholine sodium adduct 
[PC(36:3)+Na]+, and (M+2) isotope of m/z 804.55 [PC(38:7)+H]+. SU-8-based ESI microchip 
Orbitrap MS spectra of HFF and hiPSC samples with mass window of m/z 806.57 ± 0.05 (B and 
D) (publication III). 
The repeatability of the methods was evaluated with added ISTDs 
propranolol and verapamil in the cell samples. The RSD% of ISTD ion 
intensities measured using LC-MS in HFF samples were 5.1-6.0% and in hiPSC 
samples 4.2-6.1%. The RSD% measured using chip-MS for ISTDs in HFF 
samples were 8.6% and in hiPSC samples 6.4-10.6%. These results indicate 
that the repeatability within each cell sample was good with both methods. 
However, the signal intensities of the ISTDs were about two times lower in 
hiPSC samples than in HFF samples in the chip-MS measurements, but no 
significant differences were observed in the LC-MS measurements (Figure 15). 
In our experiment, the biomass of the cells was the same in all samples. 
However, the number of cells was higher in hiPSC samples (5 x 106) than in 
HFF samples (1 x 106), due to smaller size of hiPSC compared to HFF. 
Consequently, the total surface area and the amount of phospholipid 
containing cell membrane is higher in hiPSC than in HFF samples. Certain 
phospholipids, such as PCs, are known to cause ion suppression in ESI.274,275 
Thus, ion suppression might be stronger with hiPSC than with HFF samples 
when measured by chip-MS, which is more prone to ion suppression than LC-
MS. These results show that normalization using ISTDs is necessary for 
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comparison of metabolic changes between cell samples when using the chip-
MS approach. 
 
 
Figure 15 Intensity levels of ISTDs verapamil and propranolol in HFF and hiPSC samples in RP-
UHPLC-ESI-QTOF-MS (A) and SU-8-based ESI microchip Orbitrap MS (B) analysis (publication 
III). 
4.3.2 OBSERVED METABOLIC DIFFERENCES BETWEEN 
CELLS WITH LC-MS AND CHIP-MS 
 
An unsupervised PCA was performed to study the capability of both 
analytical methods to distinguish metabolic differences of the cell samples. 
PCA showed clear grouping of the cell types, indicating differences in the 
metabolic profiles of HFF and hiPSC with both analytical methods (Figure 16). 
To determine statistically significant changed features between the HFF and 
hiPSC datasets, we used t-test q-value <0.01 and fold change of at least 2 for 
the datasets acquired with chip-MS and LC-MS. A total of 435 features 
detected with the LC-MS fulfilled the criteria (q <0.01, fold >2), of which 304 
features were upregulated and 131 were downregulated in hiPSC compared to 
HFF. The number of changed features (q <0.01 and fold >2) detected with 
chip-MS was 157, of which 88 features were upregulated and 69 were 
downregulated in hiPSC. Only about one third of the changed features 
detected with LC-MS were detected with chip-MS, which is most likely due to 
the lower selectivity and higher ion suppression of chip-MS. The number of 
significantly changed features (q <0.01, fold >2) with both analytical methods 
(with a maximum mass difference of 20 ppm) was 44. These metabolites were 
tentatively identified based on their accurate masses and these are presented 
with fold changes (hiPSC/HFF) and q-values in Table 9. The fold changes 
mainly correlated well between the analytical methods, although three 
phospholipids (m/z 754.536, 834.599, and 818.603) were changed in the 
opposite direction. One possible explanation for this is peak overlap and 
domination of sodium adducts in the chip-MS measurements. The most 
downregulated compounds in hiPSC compared to HFF were N-
methylnicotinamide, creatine, L-carnitine, and PCs and PEs. The most clearly 
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upregulated metabolites in hiPSC compared with HFF were MGs, aminoadipic 
acid, choline, niacinamide, and some PCs.  
 
Figure 16 PCA score plots of normalized and scaled intensities in HFF (black) and hiPSC (red) 
samples using RP-UHPLC-ESI-QTOF-MS (A) and SU-8-based ESI microchip Orbitrap MS (B) 
(publication III).  
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Table 9 Changed metabolites between cell samples detected with both methods (q<0.01, fold >2). 
Red indicates upregulated and blue indicates downregulated metabolites in hiPSC compared with 
HFF (publication III). 
 
4.4 CAPILLARY PHOTOIONIZATION  
Many biologically important low-abundance metabolites are not detectable 
with non-targeted metabolomics methods and separate more sensitive 
methods are required. APPI and CPI have been previously shown to produce 
high sensitivity towards non-polar compounds such as steroids.142,150,154,276 
However, the suitability of CPI towards quantitative analysis of biological 
samples of large analyte groups has not been previously established. 
Accordingly, we sought to develop the previous in-house CPI prototype further 
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to increase sensitivity and robustness. The new CPI source was designed with 
a wide and low-depth ionization chamber under the wide MgF2 window to 
maximize ionization efficiency using a commercially available photoionization 
lamp with window diameter 13 mm. The wide surface area of the opening 
provides high photon flux into the ion source, ensuring high ionization 
efficiency and thus improved sensitivity. The low depth and oval shape of the 
ionization chamber were designed to minimize dead volume and dead angles. 
The volume of the ionization chamber (<0.4 mL) is negligible compared to the 
total gas flow rate through the chamber (approximately 1 L min-1). The low 
depth of the ionization chamber also ensures that a large fraction of the 
molecules entering the ion source are exposed to the ionizing photons. The 
ionization chamber was heated with a cylindrical heater embedded in a 
cylindrical aluminium block. PID temperature control of the heater and 
thermal mass of the aluminium block ensured a stable and sufficiently high 
temperature to avoid adsorptions of the analytes to the surfaces. Together, 
these modifications ensured that the design of the ionization chamber did not 
cause peak tailing, broadening, or carryover. An additional benefit of CPI was 
that positioning of the end of the transfer capillary between the 
chromatograph and CPI device is less critical than the positioning of an APPI 
sprayer in relation to the inlet orifice of a mass spectrometer. CPI was applied 
in this work as an interface between GC or LC and MS (publications IV and V).  
4.4.1 GC-CPI-MS/MS METHOD FOR ANALYSIS OF STEROIDS  
 
A GC-CPI-MS/MS method was developed for the analysis of 18 steroids from 
urine as their TMS derivatives (Table 10) (publication IV). First, the MS 
spectra of the TMS-derivatized steroids were measured to select the precursor 
ions for MS/MS analysis. Steroids formed mainly molecular ions [M]+• as base 
peaks with CPI, since the low ionization energy of TMS-derivatized steroids 
favors a charge-exchange reaction with chlorobenzene dopant molecules. For 
only CS-TMS and HC-TMS was the most intense ion [M-TMSOH]+•, in 
contrast to molecular ion, which was selected as a precursor ion. Additionally, 
the ions [M+H]+, [M-TMS]+•, [M-TMSOH]+•, and [M+O2]+• were formed and 
changes in ion ratios were observed due to changes in ambient air conditions. 
As a gas flow towards MS was higher than the gas flow provided by GC and 
dopant system, ambient air could flow into the CPI, possibly affecting the 
photoionization process. This was prevented by building up a nitrogen housing 
around the ion chamber. The nitrogen housing prevented the formation of 
other ions possibly by preventing reactions with molecules of ambient air such 
as oxygen and water (Figure 17). The nitrogen housing was further applied in 
the method development, validation, and application to urine samples. With 
the nitrogen housing, primarily molecular ion was formed, although the [M-
TMS]+• ion was also seen as a minor peak in the MS spectra of multiple steroids 
(Figure 17).  
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Table 10 Analyzed steroid precursor ions, TMS derivatives, optimized MRM transitions, and 
retention times. 
compound  RT (min) 
precursor ion 
type 
TMS-
groups 
in M 
precursor 
ion (m/z) 
quantifier 
ion (m/z) 
qualifier 
ion (m/z) 
ADT 13.38 M+• 2 434.3 161.2 195.2 
ETIOL 13.56 M+• 2 434.3 155.1 221.1 
DHEA 15.05 M+• 2 432.3 327.3 169.1 
AN 16.92 M+• 2 430.2 209.1 234.1 
T 16.99 M+• 2 432.2 209.1 301.2 
E1 17.85 M+• 2 414.2 155.1 309.2 
E2 17.98 M+• 2 416.2 285.2 129.1 
Me-T (ISTD) 19.04 M+• 2 446.3 301.2 314.3 
PREG 20.29 M+• 2 460.3 157.1 265.2 
17-OH-PREG 20.93 M+• 3 548.3 231.1 230.1 
E3 21.04 M+• 3 504.3 311.2 324.2 
PROG 21.85 M+• 2 458.3 157.1 353.2 
17-OH-PROG 22.38 M+• 3 546.3 301.2 314.2 
11-OH-PROG 23.61 M+• 3 546.3 351.3 233 
21-OH-PROG 24.77 M+• 3 546.3 301.2 230.1 
CS 24.82 [M-TMSOH]+• 5 630.3 243.1 283.1 
CORT 25.56 M+• 4 634.4 230.1 404.3 
HC 25.82 [M-TMSOH]+• 5 632.2 234.1 437.2 
A 26.02 M+• 4 648.3 305.2 233 
 
 
Figure 17 Backgroud-substracted mass spectra of ADT (A,B) and DHEA (C, D), measured from 
the same samples on the same day with (B,D) and without (A,C) nitrogen housing (publication IV). 
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The MS/MS spectra of steroid molecular ions showed similar non-specific 
fragments corresponding to the loss of CH3 [M-15]+, TMSOH [M-90]+•, CH3 + 
TMSOH [M-105]+, CH3 + 2xTMSOH [M-195]+, and [TMS]+ • peak with m/z 73 
(Figure 18). Specific fragments from the ring structure were also observed for 
all steroids. For the MRM method, two of the most intense sufficiently specific 
fragment ions were selected and optimized (Table 10). 
 
 
Figure 18 Product ion spectra of ADT (A) and DHEA (B), showing examples of typically formed 
steroid fractions in MS/MS spectra (publication IV). 
Isobaric steroids and isotopes were adequately separated when two GC 
columns were connected in tandem (Figure 19). All steroids could be 
unambiguously detected and identified based on chromatographic separation 
and selective MRM transitions. Retention times of the steroids varied between 
13.38 and 26.05 min (Figure 19). Chromatographic separation with the 
method was good, and retention time RSDs were below 1%. Peaks were 
symmetric and narrow with peak half widths in the range of 3.1 to 5.3 s. This 
indicates that the dead volume of the ion source was sufficiently small. The ion 
source and transfer line materials and temperatures were also adequate to 
avoid any cold traps, which could cause peak tailing and broadening. 
 
 
 
Figure 19 Overlaid MRM chromatograms (quantifier) of steroids analyzed from 10 ng mL-1 standard 
solution spiked in artificial urine (publication IV). 
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4.4.2 VALIDATION OF GC-CPI-MS/MS METHOD AND 
APPLICATION TO HUMAN URINE 
 
The method was validated in terms of recovery of LLE, LOD, LOQ, linearity, 
repeatability, and carryover (Table 11) (publication IV). LODs were in the 
equal range of 0.002 to 0.02 ng mL-1 for most of the steroids, with the 
exception of A, ADT, ETIOL, and HC, which had slightly higher LODs (0.05-
0.1 ng mL-1). LODs reported in the literature for GC-EI-MS analysis of steroids 
from urine have ranged from 0.5 to 20 ng mL-1 for androgenic anabolic 
steroids (AAS),277,278 0.08 to 100 ng mL-1 for endogenous androgens,164,279 5 to 
20 ng mL-1 for corticosteroids,280,281 0.001 to 0.4 ng mL-1 for estrogens,279,282 
and 0.3 to 2 ng mL-1 for progestogens.279 With LC-MS, LODs have ranged 0.1 
to 10 ng mL-1 for AAS283 and 0.02 to 113 ng mL-1 for corticosteroids.280,281,283 
LOQs for estrogens ranged from 0.02 to 0.05 ng mL-1.282,284 LODs and LOQs 
of our GC-CPI-MS method were mainly lower than the values reported 
previously in the literature,164,277–284 thus showing the high sensitivity of the 
method. Repeatability of all steroids was reasonable, with RSD values varying 
between 5% to 18% for six replicates at the level of 10 ng mL-1 and were in the 
same range as reported previously for GC-EI-MS systems.164,278,279 Linearity 
was acceptable with a coefficient of determination (R2) varying between 0.981 
to 0.996. The linear range covered 2 to 4 orders of magnitude in the range 0.05 
to 200 ng mL-1. Linear range coverage, linearity, and R2 values showed similar 
analytical performance as obtained with GC-EI-MS systems.164,278–280 LLE 
recoveries were in the range of 57.3% to 123.7%. Carryover was below 0.01% 
for all analytes. 
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Table 11 GC-CPI-MS/MS validation results; LOD, LOQ, linear range, R2 of calibration curve, 
repeatability RSD% (n=6), LLE recovery % (publication IV). *From diluted standard solutions. 
Steroid LOD     (ng mL-1) 
LOQ   
(ng mL-1) 
Linear range  
(ng mL-1) R
2 Repeatability (n= 6) 
Recovery 
(%) 
11-OH-PROG 0.02 0.2 0.2-50 0.991 11.6 82.1 
17-OH-PREG 0.01 0.1 0.1-100 0.988 12.9 122.1 
17-OH-PROG 0.01 0.5 0.5-100 0.99 10.2 123.7 
21-OH-PROG 0.002 0.2 0.2-100 0.995 5 62.9 
A 0.1 2 2-200 0.992 12.6 70.3 
ADT 0.1 2 2-100 0.988 8.5 70.2 
ADT*   100-2000 0.994   
AN 0.02 0.5 0.5-50 0.992 7.5 79.4 
CORT 0.01 0.2 0.2-20 0.993 11.1 83.4 
CS 0.01 0.5 0.5-100 0.995 17.6 75.4 
CS*   100-1000 0.997   
DHEA 0.01 0.05 0.05-100 0.996 5.3 75.7 
E1 0.01 0.1 0.1-100 0.994 10.3 72.6 
E2 0.01 0.1 0.1-100 0.995 10.3 73.6 
E3 0.005 0.1 0.1-100 0.989 5.7 81 
ETIOL 0.05 0.1 0.1-100 0.996 9 75.4 
ETIOL*   100-2000 0.997   
HC 0.05 1 1-100 0.981 18 57.3 
PREG 0.01 0.5 0.5-20 0.99 13.6 64 
PROG 0.02 0.1 0.1-100 0.995 5.5 64.3 
T 0.02 0.5 0.5-100 0.996 8.3 70.6 
 
 
The method was applied to analyze the urine of eight volunteers (4 females 
and 4 males) (Table 12). The determined concentrations of most of the steroid 
glucuronide conjugates were higher or at the same level compared with the 
respective free steroids, and only 11-OH-PROG and 17-OH-PROG showed 
levels below the LOQ in all samples also as glucuronide conjugates (Table 12). 
The glucuronides of ADT and ETIOL are the main endogenous metabolites of 
testosterone and were excreted in urine at high concentrations (100-2000 ng 
mL-1), as reported previously.285 The corticosteroids CS and HC had the 
highest observed free-form concentrations (10-100 ng mL-1) and were at the 
same level as their glucuronide conjugates and consistent with earlier 
findings.286 Clear differences in male and female samples regarding sex 
steroids were observed and steroid concentrations (T, E1, E2, E3, DHEA) were 
consistent with previous studies.279,282,284,285 The detected concentrations of 
DHEA glucuronide were in the range of 10 to 40 ng mL-1; the mean value 
reported in the literature in a study of over 3000 subjects was approximately 
35 ng mL-1.285,286 The data showed clear differences in male and female 
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samples regarding sex steroids; testosterone was higher in males (mean 16.9 
ng mL-1 in males, 1.8 ng mL-1 in females) and estrogens were higher in females 
(>2 fold difference in the mean values), consistent with the literature.279,284,285 
Additionally, small concentrations of AN and CORT were detected in free form 
and 17-OH-PREG, 21-OH-PREG, A, AN, CORT, and PREG as glucuronide 
conjugates.  
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4.4.3 CPI AS AN INTERFACE FOR LOW FLOW RATE LC-MS 
 
The CPI-type ion source has been shown to be sensitive and suitable for 
volatile and semi-volatile compounds by GC-MS or DI-MS. However, use as 
an interface in LC-MS has not been shown previously. The feasibility of 
coupling low flow rate LC to MS with CPI interface was studied by analyzing 
the steroids DHEA, E2, PROG, and T (publication V). The advantage of CPI 
compared with common free-space APPI sources is that all eluent and analyte 
molecules are directed into the CPI device connected directly to the glass inlet 
capillary of the mass spectrometer. As the vaporization and ionization of 
analytes take place inside the heated CPI capillary, the ion transfer into the 
vacuum of the MS is improved.  
The main operational parameters (CPI temperature and flow rate) of the 
CPI device were optimized using a UPLC with a splitter. The effect of CPI 
temperature to the signal intensity was tested between 225-350oC using an 
eluent MeOH with flow rate of 10 μL min-1 to the CPI. The signal intensity 
increased when the temperature was raised from 225oC to 250-275oC and 
decreased at higher temperatures (Figure 20A). At lower temperatures, the 
vaporization of eluent and desolvation of analyte ions are inefficient, resulting 
in low signal intensity. The signal decrease at higher CPI temperatures may be 
partly due to formation of smaller cluster ions with higher temperatures, 
which increases the mobility of cluster ion and the possibility for charge 
neutralization through collisions to CPI capillary walls. At higher CPI 
temperatures, precursor ions of analytes may also thermally dissociate, 
resulting in decreased sensitivity.    
 
 
Figure 20 The effect of CPI capillary temperature (A) and flow rate (B) on detected signal from a 
standard solution of 100 ng mL-1.  Published by The Royal Society of Chemistry (publication V). 
The effect of LC eluent flow rate on the signal intensity was studied at flow 
rates between 10-40 μL min-1 (CPI temperature 275°C). The optimal flow rate 
was 10 μL min-1 and signal of steroids decreased with higher flow rates (Figure 
20B). However, estradiol behaved differentially as its signal increased at a flow 
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rate of 20 μL min-1 and then decreased similarly as the other steroids. Reduced 
signal intensity with higher flow rates is probably due to a combination of 
several factors. One possible explanation for the decreased signal at higher 
flow rates is the inefficient heat transfer that is unable to completely vaporize 
the eluent before the ionization chamber. As photoionization occurs in the gas 
phase, incomplete vaporization of eluent can decrease the ionization efficiency 
of the analytes. The higher flow rate also increases the solvent cluster ion size, 
which again increases the proton affinity of the cluster ion. It is possible that 
the protonation of the analytes becomes less favorable when solvent cluster 
ion size is increased. Additionally, the photoionization efficiency of the dopant 
might be decreased with higher flow rates, since the photons are absorbed by 
the eluent in the ion source. 
           The feasibility of UPLC-CPI-MS/MS for quantitative analysis of selected 
steroids was studied in terms of linearity, repeatability, and LOD with 
standard samples (Table 13). The flow rate in UPLC was 200 μL min-1, the 
injection volume was 10 μL, and the flow was split after the column with a ratio 
of 1:20. As a result, the flow rate and the sample volume to the CPI were 10 μL 
min-1 and 0.5 μL, respectively. Linearity was studied with a sample 
concentration range of 5-400 ng mL-1 (2.5-200 pg to the CPI). Linearity was 
good with correlation coefficient (R) levels between 0.990-0.998. The 
repeatability of injection was determined at the concentration level 10 ng mL-
1 (5 pg to the CPI). Repeatability was acceptable with RSD% values between 3-
20% (n=6). The LODs (S/N >3) were between 0.5-2.5 pg injected to CPI (1-5 
ng mL-1 in a sample), which indicates good sensitivity of the method.  
 
Table 13 LODs (amount injected to CPI), linearity, and repeatability of steroids using UPLC-CPI-
MS/MS. Published by The Royal Society of Chemistry (publication V). 
 
 
 
 
 
 
 
 
The sensitivity of the UPLC-CPI-MS (flow rate to CPI 10 μL min-1) 
method was also compared to the standard UPLC-APPI-MS (flow rate 200 μL 
min-1) method by injecting 10 μL of standard sample including the four test 
steroids at a concentration of 10 ng mL-1. As the splitter (1:20) was used in 
UPLC-CPI-MS, but not in UPLC-APPI-MS, the analyte amount eluting to the 
APPI source was 100 pg and 5 pg to the CPI source. The peak areas were 7.4-
15.6 times higher with the standard UPLC-APPI-MS than with UPLC-CPI-
APPI, although 20 times more intense signals could be expected with standard 
Compound     
     LOD 
      (pg) 
Linearity 
(R) 
Repeatability RSD%  
 (10 ng mL-1, n=6) 
Estradiol     0.5       0.997                  3.2 
Testosterone     1.25     0.994                 12.7 
DHEA     2.5        0.998                 20.1 
Progesterone     2.5        0.990                 13.2 
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APPI. This shows that the sensitivity with CPI is at least at the same level as 
with standard APPI.  
The feasibility of CPI in coupling of capillary LC to MS was demonstrated 
by analyzing a standard sample (10 ng mL-1) (Figure 21). The flow rate was 10 
μL min-1 and the injection volume was 1 μL, corresponding 10 pg injected into 
the column. All four steroids were detected, showing that CPI is a potential 
method for coupling of low flow rate LC to MS and is especially suitable for the 
analysis of low-volume samples. 
 
 
Figure 21 Selected reaction monitoring chromatograms of PROG, T, DHEA, and E2 from a 
standard mixture of 10 ng mL-1 using capillary LC-CPI-MS/MS. Published by The Royal Society of 
Chemistry (publication V). 
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5 SUMMARY AND CONCLUSIONS 
The overall aim of this study was to apply mass spectrometry-based 
methods for metabolomics and to develop new analytical methods for 
metabolite analysis of biological samples. 
A multiomics study of neonatal mouse hearts revealed several altered 
metabolites and metabolic pathways during the early postnatal period. For 
example, a transition from carbohydrates to lipids as the main energy source, 
an overall increase in energy metabolism, and increased oxidative stress was 
observed in the postnatal period based on changes in the metabolite levels. In 
combination with other omics, BCAA degradation, fatty acid metabolism, 
mevalonate pathway, and ketogenesis showed a potential role in the regulation 
of neonatal cardiomyocyte proliferation. Overall, this study provided an 
extensive resource for molecule abundances for future mechanistic studies. 
Integration of data from several omics experiments increased the reliability of 
the findings and provided comprehensive knowledge of neonatal metabolism. 
However, we noted that all omics had limited coverage of detected species and 
the datasets did not necessary support each other due to differences in 
turnover rates, which makes the integration of data a challenging task. The 
development of more complex mechanistic models and computational tools 
for multiomics will probably improve the possibilities to gain even further 
insights.287  
A metabolomics study of serum from non-diabetic individuals revealed 19 
serum metabolite clusters that were significantly associated with the IR 
phenotype, including in total 26 polar metabolites from five separate clusters 
and 367 lipids from 14 clusters. The IR phenotype was positively associated 
with polar metabolites and lipid clusters and negatively (IS phenotype) 
associated with lipid clusters. These clusters also showed significant 
associations with gut microbiota functional modules. The serum metabolome 
of insulin-resistant individuals showed increased levels of BCAAs, which 
correlated with a gut microbiome that had an enriched biosynthetic potential 
for BCAAs and was deprived of genes encoding bacterial inward transporters 
of these BCAAs. P. copri and B. vulgatus were identified as the main species 
driving the association between biosynthesis of BCAAs and IR. Mouse studies 
demonstrated that P. copri can induce IR, aggravate glucose intolerance, and 
increase circulating levels of BCAAs. Our findings showed that the human gut 
microbiota impacts the serum metabolome and contributes to IR, suggesting 
that microbial targets may have the potential to reduce IR and the occurrence 
of metabolic and cardiovascular disorders.  
Microchip-MS is considered a potential technique for metabolomics 
research, as it allows a rapid, straightforward analysis from low sample volume 
and the possibility for a completely automated analytical system in the future. 
The feasibility of chip-MS for non-targeted metabolomics was studied and 
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compared to the commonly applied LC-MS for non-targeted metabolomics 
analysis of HFF and hiPSC cells. The comparison of chip-MS and LC-MS for 
global non-targeted metabolomics showed that both methods were capable of 
detecting metabolic differences between cell types and could distinguish the 
cells based on their metabolic profiles. The study demonstrated that chip-MS 
was a rapid and simple method that allowed high sample throughput from 
small sample volumes. Although selectivity and metabolite coverage of chip-
MS was limited compared to LC-MS, chip-MS showed more universal 
metabolite coverage from polar metabolites to lipids. As a drawback, chip-MS 
seemed to suffer more from ion suppression. 
All the applied non-targeted metabolomics platforms (publications I-III) 
were capable of detecting metabolic differences and showed acceptable 
analytical performance. Both LC-MS and GCxGC-MS are suitable for 
metabolic profiling, although GC separation is limited to low molecular weight 
compounds and adequate separation of a wide range of metabolites using LC-
MS requires more than one column chemistry. HILIC serves as an alternative 
for GCxGC-MS for detection of polar metabolites without a requirement for 
time-consuming derivatization.172 Thus, the simultaneous detection of polar 
metabolites and lipids with two parallel separations with C18 and HILIC shows 
promising results for replacing two individual platforms.88  
Applying two complimentary analytical approaches (i.e. LC-MS and 
GCxGC-MS) (publication I and II) increased the metabolite coverage and 
expanded the polarity range of detected metabolites. A separate analysis of 
lipidomics and polar metabolites also enabled the detection of non-polar lipid 
classes such as TGs and ChoEs (publication II). Although two complimentary 
platforms for metabolomics were applied, the overall metabolite coverage was 
still quite low compared to the number of existing metabolites and some 
metabolites were not detectable with the methods employed due to low 
abundance or unsuitable methodologies. Analysis in negative ion mode in LC-
MS and chip-MS methods would have increased the metabolite coverage to 
metabolite and lipid classes such as PA, PI, PG, PS, organic acids, and sugars, 
which are poorly detected in positive ion mode.12,288 However, with the applied 
instruments, this would have doubled the analysis time and limited the sample 
throughput, which is highly important in metabolomics of large sample series. 
From the applied methods in this work, only chip-MS (publication III) would 
allow high throughput even with analysis of both polarities and the metabolite 
coverage could be feasibly expanded with chip-MS through several 
measurements without a significant increase in time. Polarity switching in 
instruments with such capability is becoming more feasible, with the ability to 
detect both polarities in one run. However, the eluent composition affects the 
ionization efficacies and maximal sensitivity is not obtained for both polarities 
simultaneously.289  
Most of the detected features remained unknown due to limited spectral 
libraries and identification capabilities. The identification of metabolites is the 
bottleneck of non-targeted metabolomics,227,236 as also observed in this study. 
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In general, EI-MS libraries are considered more applicable due to high 
repeatability of spectra and RIs available.  However, ESI MS/MS libraries are 
expanding rapidly, quality of comparison spectra are improving, and spectra 
are obtained with multiple experimental conditions.227,236  In our studies, EI-
MS spectral identification capabilities were also limited. The detected features 
with GCxGC-MS and LC-MS remained as frequently unidentified. Although 
non-targeted metabolomics in principal offers the opportunity to discover 
novel compounds, the findings are quite often limited to already existing 
databases. Mechanism studies are also limited to already known metabolic 
pathways and the complexity of the metabolic networks are partly unrevealed. 
In particular, lipid-containing networks and functions of individual lipid 
species are widely unknown, which hinders biological interpretation. 
In general, non-targeted methods are considered to be less reliable and 
repeatable than targeted methods.17 The automated peak picking with 
different algorithms is more prone to errors when compared with targeted 
methods where the integrations are usually inspected manually, which is not 
feasible in non-targeted methods with even thousands of detected features. 
Several significant findings with LC-MS (publications I-III) were confirmed by 
also manually inspecting the peaks and alignment, and no false findings were 
observed. This shows that the applied algorithms work quite well. However, 
careful selection of peak picking parameters is necessary and caution is 
required if some drift in the signal intensity or mass accuracy is observed. The 
signal drift in targeted methods is usually corrected with labeled ISTDs, 
whereas in non-targeted methods only a few or no ISTDs are used to correct 
the signal. In lipidomics (publication II), the repeatability was improved with 
normalization of lipid group-specific ISTDs and good repeatability was 
obtained for identified lipids in the control serum sample. Even better 
repeatability could be obtained with an approach using metabolites extracted 
from 13C-labeled yeast acting as labeled ISTDs for multiple metabolites or 
lipids simultaneously. Labeled ISTDs can be used to normalize or quantitate 
the metabolites for better accuracy and wider linear dynamic range.290–292  
All non-targeted methods, including the methods presented in this thesis, 
are a compromise between wide metabolite coverage, high throughput, 
simplicity of operation, good repeatability, and accuracy. Overall, our methods 
were suitable for non-targeted metabolomics and showed similar and expected 
analytical performance and throughput as reported.12,60,63,167,293 
Since non-targeted metabolomics are incapable of detecting biologically 
important low-abundance metabolites, targeted methods are also required for 
certain analytes to improve sensitivity. A developed CPI source was applied for 
the analysis of steroids with GC-CPI-MS/MS from urine samples. The 
developed ionization chamber showed high ionization efficacy and ion 
transmission to non-polar steroids. The TMS-derivatized steroids formed 
mainly abundant molecular ions with minimal fragmentation and formation 
of other ions. The developed GC-CPI-MS/MS method showed good 
chromatographic resolution, acceptable linearity and repeatability, and low 
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LODs. The feasibility of the ion source for the quantitative analysis of 
biological samples was studied by analyzing 18 endogenous steroids in urine. 
In total, 15 steroids were quantified either as a free steroid or glucuronide 
conjugate from human urine samples and the detected steroid levels were 
consistent with the literature.279,282,284–286 Overall, the CPI ion source showed 
potential for quantitative analysis of non-polar low abundance metabolites. 
The CPI interface would also allow combining GC with hyphenated high-
resolution API mass spectrometers, which introduces the possibility to use GC 
for non-targeted metabolomics analysis to discover elemental compositions of 
unknowns. Since there is some evidence that the fragmentation of formed 
molecular ions follows the same odd-electron fragmentation pathways as in 
EI,142 it might still be possible to use EI spectral libraries for identification of 
MS/MS spectra. 
The CPI interface was also combined for the first time with LC using low 
flow rates. The feasibility of LC-CPI-MS/MS for the quantitative analysis of 
four steroids was studied and the method showed good quantitative 
performance and high sensitivity. The LC-CPI-MS/MS was applicable with 
low flow rates, which are not optimal for existing commercial atmospheric 
pressure ion source geometries. This offers an alternative for nanoESI, which 
is exclusively used in nano- or capillary-LC applications. In conclusion, CPI 
ion source showed good potential in combination with both LC and GC and 
allowed the usage of the same API mass spectrometer with both separation 
techniques. With CPI, high sensitivity to non-polar compounds can be 
obtained and the source is applicable for quantitative analysis of biological 
samples. 
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